Gevo (GEVO) 10-Q12 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Oct. 31, 2014
Document Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'GEVO	'
Entity Registrant Name	'GEVO, INC.	'
Entity Central Index Key	'0001392380	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	99,592,858

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$14,010	$24,625
Accounts receivable	2,042	1,358
Inventories	4,027	3,581
Prepaid expenses and other current assets	861	1,163
Total current assets	20,940	30,727
Property, plant and equipment, net	82,510	83,475
Debt issue costs, net	567	801
Restricted deposits	2,611	'
Deposits and other assets	853	1,352
Total assets	107,481	116,355
Current liabilities:	'	'
Accounts payable and accrued liabilities	7,433	13,030
Current portion of secured debt, net of $34 and $492 discount at September 30, 2014 and December 31, 2013, respectively	253	788
Derivative warrant liability	2,877	7,243
Total current liabilities	10,563	21,061
Long-term portion of secured debt, net of $25 and $450 discount at September 30, 2014 and December 31, 2013, respectively	561	9,339
2017 notes recorded at fair value	25,564	'
2022 notes, net	12,920	14,501
Other long-term liabilities	348	479
Total liabilities	49,956	45,380
Commitments and Contingencies (see note 12)	'	'
Stockholders' Equity	'	'
Preferred stock, $0.01 par value per share; 10,000,000 shares authorized; none issued and outstanding at September 30, 2014 and December 31, 2013	'	'
Common stock, $0.01 par value per share; 250,000,000 authorized; 99,592,898 and 68,492,894 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	991	685
Additional paid-in capital	348,753	332,443
Deficit accumulated	-292,219	-262,153
Total stockholders' equity	57,525	70,975
Total liabilities and stockholders' equity	$107,481	$116,355

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock shares issued	99,592,898	68,492,894
Common stock, shares outstanding	99,592,898	68,492,894
Current Portion Debt	'	'
Secured debt, discount	$34	$492
Long-Term Portion Debt	'	'
Secured debt, discount	$25	$450

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue and cost of goods sold	'	'	'	'
Hydrocarbon revenue	$778	$704	$3,426	$2,016
Grant and other revenue	166	406	620	1,168
Total revenues	10,141	1,127	18,765	6,529
Cost of goods sold	11,760	4,730	24,709	9,474
Gross loss	-1,619	-3,619	-5,944	-6,336
Operating expenses	'	'	'	'
Research and development	3,723	5,476	11,414	16,280
Selling, general and administrative	3,570	6,668	13,508	19,897
Other operating expenses	0	0	0	0
Total operating expenses	7,293	12,144	24,922	36,177
Loss from operations	-8,912	-15,763	-30,866	-42,513
Other (expense) income	'	'	'	'
Interest expense	-2,017	-1,733	-6,227	-7,321
Interest expense - debt issuance costs	-581	'	-3,766	'
Loss on conversion of debt	'	'	'	-2,038
Gain from change in fair value of embedded derivative of the 2022 Notes	726	1,587	3,470	2,280
Gain from change in fair value of derivative warrant liability	4,173	'	6,772	'
Gain from change in fair value of 2017 Notes	5,673	'	544	'
Other income	'	24	7	115
Total other income (expense)	7,974	-122	800	-6,964
Net loss	-938	-15,885	-30,066	-49,477
Deemed dividend - amortization of beneficial conversion feature on Series D-1 preferred stock	0	0	0	0
Net loss attributable to Gevo, Inc. common stockholders	-938	-15,885	-30,066	-49,477
Net loss per share attributable to Gevo, Inc. common stockholders - basic and diluted	($0.01)	($0.34)	($0.40)	($1.14)
Weighted-average number of common shares outstanding - basic and diluted	87,121,184	46,052,867	74,354,906	43,492,291
Ethanol	'	'	'	'
Revenue and cost of goods sold	'	'	'	'
Sales	9,197	'	14,719	'
Corn	'	'	'	'
Revenue and cost of goods sold	'	'	'	'
Sales	'	17	'	3,345
Cost of goods sold	'	$16	'	$3,391

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating Activities	'	'
Net loss	($30,066)	($49,477)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Gain from change in fair value of derivative warrant liability	6,772	'
Gain from change in fair value of embedded derivative of 2022 note	-3,470	-2,280
Gain from change in fair value of 2017 note	-544	'
Non-cash stock-based compensation	2,362	3,083
Depreciation and amortization	3,214	2,558
Non-cash interest expense	6,374	3,747
Loss on conversion of debt	'	2,038
Loss from change in fair value of derivatives	'	175
Other non-cash expenses	'	649
Changes in operating assets and liabilities:	'	'
Accounts receivable	-685	-169
Inventories	-446	1,814
Prepaid expenses and other current assets	302	239
Deposits and other assets	'	-49
Accounts payable, accrued expenses, and long-term liabilities	-2,875	5,952
Net cash used in operating activities	-32,606	-31,720
Investing Activities	'	'
Acquisitions of property, plant and equipment	-4,553	-4,524
Proceeds from sales tax refund	'	1,896
Restricted deposits	-2,611	'
Net cash used in investing activities	-7,164	-2,628
Financing Activities	'	'
Payments on secured debt	-9,720	-6,715
Debt and equity offering costs	-5,051	'
Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan	19	59
Proceeds from issuance of common stock and common stock units	18,000	'
Proceeds from issuance of 2017 Notes	25,907	'
Deposit on secured debt and other	'	-79
Net cash (used in) provided by financing activities	29,155	-6,735
Net (decrease) increase in cash and cash equivalents	-10,615	-41,083
Cash and cash equivalents	'	'
Beginning of period	24,625	66,744
Ending of period	14,010	25,661
Supplemental disclosures of cash and non-cash investing and financing transactions	'	'
Cash paid for interest, net of interest capitalized	3,697	3,805
Capitalization of interest, from 2017 Convertible Notes	201	'
Non-cash purchase of property, plant and equipment	99	5,875
Issuance of common stock for services	'	483
Issuance of common stock warrants	2,400	'
Common Stock	'	'
Supplemental disclosures of cash and non-cash investing and financing transactions	'	'
Conversion of convertible debt to common stock	'	$12,784

Nature_of_Business_Financial_C

Nature of Business, Financial Condition and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Nature of Business, Financial Condition and Basis of Presentation	'
	1. Nature of Business, Financial Condition and Basis of Presentation
	Nature of Business. Gevo, Inc. (“Gevo” or the “Company,” which, unless otherwise indicated, refers to Gevo, Inc. and its subsidiaries) is a renewable chemicals and next generation biofuels company focused on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Gevo, Inc. was incorporated in Delaware on June 9, 2005. Gevo, Inc. formed Gevo Development, LLC (“Gevo Development”) in September 2009 to finance and develop biorefineries either through joint venture, licensing arrangements, tolling arrangements or direct acquisition (see Note 9). Gevo Development became a wholly owned subsidiary of the Company in September 2010. Gevo Development purchased Agri-Energy, LLC (“Agri-Energy”) in September 2010. Through May 2012, Agri-Energy, a wholly owned subsidiary of Gevo Development, was engaged in the business of producing and selling ethanol and related products produced at its plant located in Luverne, Minnesota (the “Agri-Energy Facility”). The Company commenced the retrofit of the Agri-Energy Facility in 2011 and commenced initial startup operations for the production of isobutanol at this facility in May 2012. In September 2012, the Company made the strategic decision to pause isobutanol production at the Agri-Energy Facility to focus on optimizing specific parts of the process to further enhance isobutanol production rates. In 2013, the Company modified the Agri-Energy Facility in order to increase the isobutanol production rate. In June 2013, the Company resumed the limited production of isobutanol, operating one fermenter and one Gevo Integrated Fermentation Technology® (“GIFT®”) separation system in order to (i) verify that the modifications had significantly reduced the previously identified infections, (ii) demonstrate that its biocatalyst performs in the one million liter fermenters at the Agri-Energy Facility, and (iii) confirm GIFT® efficacy at commercial scale at the Agri-Energy Facility. In August 2013, the Company expanded production capacity at the Agri-Energy Facility by adding a second fermenter and second GIFT® system to further verify its results with a second configuration of equipment. In October 2013, the Company began commissioning the Agri-Energy Facility on corn mash to test isobutanol production run rates and to optimize biocatalyst production, fermentation separation and water management systems. In March 2014, the Company decided to leverage the flexibility of its GIFT® technology and further modify the Agri-Energy Facility which it believes will enable the simultaneous production of isobutanol and ethanol. In July 2014, the Company began more consistent co-production of isobutanol and ethanol at the Agri-Energy Facility, with one fermenter utilized for isobutanol production and three fermenters utilized for ethanol production. In line with the Company’s strategy to maximize asset utilization and site cash flows, the Company believes that this configuration of the plant should allow it to continue to optimize its isobutanol technology at a commercial scale, while taking advantage of the positive ethanol contribution margins currently available in the marketplace.
	At September 30, 2014, the Company continues to conduct research and development, business development, business and financial planning, establishing its facilities including retrofitting the Agri-Energy Facility, initial startup operations for isobutanol production at the Agri-Energy Facility and raising capital. Ultimately, the Company believes that the attainment of profitable operations is dependent upon future events, including completion of its development activities resulting in commercial production and sales of isobutanol or isobutanol-derived products and/or technology, obtaining adequate financing to complete its development activities, obtaining adequate financing to build out further isobutanol production capacity, gaining market acceptance and demand for its products and services, and attracting and retaining qualified personnel.
	The Company has primarily derived revenue from the sale of ethanol, distiller’s grains and other related products produced as part of the ethanol production process at the Agri-Energy Facility. The production of ethanol alone is not the Company’s intended business and its future strategy is expected to depend on its ability to produce and market isobutanol and products derived from isobutanol. Given that the production of ethanol alone is not the Company’s intended business, and the Company is only beginning to achieve more consistent production and revenue from the sale of isobutanol, the historical operating results of Agri-Energy may not be indicative of future operating results for Agri-Energy or Gevo.



	Financial Condition. For the three and nine months ended September 30, 2014, the Company incurred a consolidated net loss of $0.9 million and $30.1 million, respectively, and had an accumulated deficit of $292.2 million. The Company’s cash and cash equivalents at September 30, 2014 totaled $14.0 million which is primarily being used for the following: (i) operating activities and completion of the side-by-side configuration of the Agri-Energy Facility; (ii) operating activities at its corporate headquarters in Colorado, including research and development work; (iii) capital improvements primarily associated with its Agri-Energy Facility; (iv) costs associated with optimizing isobutanol production technology; (v) costs associated with the ongoing litigation with Butamax Advanced Biofuels LLC (“Butamax”), a joint venture between British Petroleum (“BP”), E.I. du Pont de Nemours and Company (“DuPont”), and Dupont and BP Biofuels; and (vi) debt service obligations. The Company expects to incur future net losses as it continues to fund the development and commercialization of its product candidates. The Company’s transition to profitability is dependent upon, among other things, the successful development and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability or positive cash flows, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources, it may seek to restructure its debt and it will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds, or achieve or sustain profitability or positive cash flows from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. Based on the Company’s current operating plan, the Company believes that the current levels of cash will fund planned operations into 2015 without additional sources of cash.
	Despite the Company’s continued success in meeting isobutanol fermentation targets, producing isobutanol and ethanol simultaneously, and its progress toward achieving breakeven earnings before interest, taxes, depreciation and amortization (EBITDA) at the Agri-Energy Facility, the Company continues to face significant expenses related to its ongoing litigation with Butamax. While the United States District Court has temporarily stayed the litigation with Butamax involving certain patents, trials related to other patents were recently scheduled for August 2015 and April 2016 and the Company expects to incur significant costs preparing for and participating in these upcoming trials. The Company continues to believe that the Butamax complaints are without merit. However, if it is unable to raise the significant funds that will be required for it to continue to defend its freedom to operate, the Company could be forced to change its business strategy which may include one or more of the following: (i) terminating the research and development, manufacture, sale and use of products that include the subject intellectual property; (ii) conducting research and development and manufacturing any products that include the subject intellectual property outside of the United States; (iii) shifting its focus to the production of ethanol and/or the development of hydrocarbon products, including those that can be produced from ethanol; or (iv) pursuing strategic alternatives, including the monetization of some or all of the Company’s assets, in order to maximize stockholder value.
	Basis of Presentation. The unaudited consolidated financial statements of the Company (which include the accounts of its wholly-owned subsidiaries Gevo Development and Agri-Energy) have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. These statements reflect all normal and recurring adjustments which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows of the Company at September 30, 2014 and for all periods presented. The consolidated statements of operations for the three and nine months ended September 30, 2014 and consolidated statements of cash flows for the nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto included under the heading “Financial Statements and Supplementary Data” in Part II, Item 8 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (the “Annual Report”).

	Significant accounting policies. The Company has elected the fair value option for certain long-term debt instruments that qualify for such treatment. See Note 7 for a detailed description of the accounting for the 2017 convertible notes that are accounted for in this manner. The Company also placed into service the Retrofit asset (as defined below) in July of 2014 and began depreciating the asset over a 20 year useful life.
	Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014‑09”). The objective of ASU 2014-09 is to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014‑09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014‑09.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). The amendments in ASU 2014-10 remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification®. ASU 2014-10 is effective for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted and the Company adopted ASU 2014-10 in the third quarter of 2014 which consisted principally of removing Inception to date information on the Company’s statements of operations, equity and cash flows as well as other inception to date disclosures in the notes to the consolidated financial statements.

Earnings_per_Share

Earnings per Share	9 Months Ended
Earnings per Share	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings per Share	'
	2. Earnings per Share
	Basic net loss per share is computed by dividing the net loss attributable to Gevo, Inc. common stockholders for the period by the weighted-average number of common shares outstanding during the period. Diluted earnings per share (“EPS”) includes the dilutive effect of common stock equivalents and is computed using the weighted-average number of common stock and common stock equivalents outstanding during the reporting period. Diluted EPS for the three and nine months ended September 30, 2014 and 2013 excluded common stock equivalents because the effect of their inclusion would be anti-dilutive, or would decrease the reported loss per share.
	The following table sets forth securities outstanding that could potentially dilute the calculation of diluted earnings per share.

		Nine Months Ended September 30,
		2014		2013
	Warrants to purchase common stock		37,563,548		1,259,998
	Convertible 2017 notes		22,537,983		-
	Convertible 2022 notes		4,725,516		4,725,392
	Outstanding options to purchase common stock		3,741,150		3,172,213
	Unvested restricted common stock		1,010,220		1,033,731
	Total		69,578,417		10,191,334

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	3. Inventories
	The following table sets forth the components of the Company’s inventory balances (in thousands).

		September 30,		December 31,
		2014		2013
	Raw materials
	Corn	$	1,376	$	1,456
	Enzymes and other inputs		376		514
	Finished goods		623		192
	Work in process		228		224
	Spare parts		1,424		1,195

	Total inventories	$	4,027	$	3,581
	Included in cost of goods sold is depreciation of $1.4 million and $0.5 million during the three months ended September 30, 2014 and 2013, respectively, and $2.5 million and $1.6 million during the nine months ended September 30, 2014 and 2013, respectively.

Property_Plant_and_Equipment

Property, Plant and Equipment	9 Months Ended
Property, Plant and Equipment	Sep. 30, 2014
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment	'
	4. Property, Plant and Equipment
	The following table sets forth the Company’s property, plant and equipment by classification (in thousands).

		Useful	September 30,			December 31,
		Life	2014			2013
	Construction in progress	-	$	356		$	66,033
	Plant machinery and equipment	10 years		13,093			11,009
	Site improvements	10 years		7,009			7,007
	Retrofit asset	20 years		65,659			-
	Lab equipment, furniture and fixtures and vehicles	5 years		6,369			6,303
	Demonstration plant	2 years		3,597			3,597
	Buildings	10 years		2,543			2,543
	Computer, office equipment and software	3 years		1,465			1,437
	Leasehold improvements, pilot plant, land and support equipment	2 - 5 years		2,143			2,105
	Total property, plant and equipment			102,234			100,034
	Less accumulated depreciation and amortization			(19,724	)		(16,559	)

	Property, plant and equipment, net		$	82,510		$	83,475
	The Retrofit asset was placed in service in the third quarter of 2014 and is being depreciated over 20 years.
	Prior to the first quarter of 2014, the Company capitalized interest on its secured debt associated with its qualifying assets, which related to the retrofit of the Agri-Energy Facility (“Retrofit asset”) that was actively being developed. The Company did not capitalize any interest during the three and nine months ended September 30, 2014 as there were no qualifying assets which were actively being developed. The Company capitalized $0.1 million and $0.2 million of interest during the three and nine months ended September 30, 2013, respectively.

Derivative_Instruments

Derivative Instruments	9 Months Ended
Derivative Instruments	Sep. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Instruments	'
	5. Derivative Instruments
	Forward Purchase and Exchange-Traded Futures Contracts
	The Company’s activities generally expose it to a variety of market risks, including the effects of changes in commodity prices such as corn. These financial exposures are monitored and have been managed by the Company through derivative instruments, including forward purchase contracts and exchange traded futures contracts, as an integral part of its overall risk management program. The Company’s risk management program focuses on the unpredictability of financial and commodities markets and seeks to reduce the potentially adverse effects that the volatility of these markets may have on its operating results.
	The Company has historically followed a policy of using exchange-traded futures contracts as a means of managing its exposure to fluctuations in operating margins based on changes in commodity prices. The Company did not have any exchange-traded futures contracts as of September 30, 2014. During the three and nine months ended September 30, 2013, exchange-traded futures contracts were valued at fair value and changes in fair value are recorded in cost of goods sold in the consolidated statements of operations.
	Forward purchase contracts are recorded at fair value unless a company elects to use the “normal purchases and normal sales scope exception” guidance of GAAP. To qualify for the normal purchases and normal sales scope exception, a contract must be appropriately designated and must provide for the purchase or sale of physical commodities in quantities that are expected to be used or sold over a reasonable period of time in the normal course of operations. The Company did not have forward purchase contracts during the three and nine months ended September 30, 2014. During the three and nine months ended September 30, 2013, the Company did not elect the normal purchase and normal sales scope exception to its forward purchase contracts.
	The foregoing derivatives do not include any credit risk related contingent features, the Company has not entered into these derivative financial instruments for trading or speculative purposes, and it has not designated any of its derivatives as hedges for financial accounting purposes. At September 30, 2014 and December 31, 2013, the Company did not have any exchange-traded futures contracts or forward purchase contracts and, as such, did not hold any cash in margin deposit accounts.
	The following table summarizes the realized and unrealized gain / (loss) of the Company’s derivative instruments (in thousands).

		Three Months Ended September 30,						Nine Months Ended September 30,
	Realized Gain / (Losses)	2014			2013			2014		2013
	Exchange-traded futures contracts	$	-		$	168		$	-	$	490

	Unrealized Gain / (Losses)
	Exchange-traded futures contracts		-			42			-		(176	)
	Forward purchase contracts		-			(11	)		-		1

	*Convertible 2022 Notes*
	In July 2012, the Company issued 7.5% convertible senior notes due 2022 (the “2022 Notes”) which contain the following embedded derivatives: (i) rights to convert into shares of the Company’s common stock, including upon a Fundamental Change (as defined in the indenture governing the 2022 Notes (the “Indenture”)); and (ii) a Coupon Make-Whole Payment (as defined in the Indenture) in the event of a conversion by the holders of the 2022 Notes prior to July 1, 2017. Embedded derivatives are separated from the host contract, the 2022 Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. The Company has concluded that the embedded derivatives within the 2022 Notes meet these criteria and, as such, must be valued separate and apart from the 2022 Notes as one embedded derivative and recorded at fair value each reporting period.
	The Company used a binomial lattice model in order to estimate the fair value of the embedded derivative in the 2022 Notes. A binomial lattice model generates two probable outcomes, whether up or down, arising at each point in time, starting from the date of valuation until the maturity date. A lattice was initially used to determine if the 2022 Notes would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the 2022 Notes will be converted early if the conversion value is greater than the holding value; or (ii) the 2022 Notes will be called if the holding value is greater than both (a) the Redemption Price (as defined in the Indenture) and (b) the conversion value plus the Coupon Make-Whole Payment at the time. If the 2022 Notes are called, then the holders will maximize their value by finding the optimal decision between (1) redeeming at the Redemption Price and (2) converting the 2022 Notes.
	Using this lattice, the Company valued the embedded derivative using a “with-and-without method,” where the value of the 2022 Notes including the embedded derivative, is defined as the “with”, and the value of the 2022 Notes excluding the embedded derivative, is defined as the “without”. This method estimates the value of the embedded derivative by looking at the difference in the values between the 2022 Notes with the embedded derivative and the value of the 2022 Notes without the embedded derivative. The lattice model requires the following inputs: (i) price of Gevo common stock; (ii) Conversion Rate (as defined in the Indenture); (iii) Conversion Price (as defined in the Indenture); (iv) maturity date; (v) risk-free interest rate; (vi) estimated stock volatility; and (vii) estimated credit spread for the Company.
	The following table sets forth the inputs to the lattice model that were used to value the embedded derivative.

		September 30,			December 31,
		2014			2013
	Stock price	$	0.34		$	1.43
	Conversion Rate		175.6697			175.6697
	Conversion Price	$	5.69		$	5.69
	Maturity date	1-Jul-22			1-Jul-22
	Risk-free interest rate		2.3	%		2.8	%
	Estimated stock volatility		85	%		65	%
	Estimated credit spread		20	%		33	%

	The following table sets forth the value of the 2022 Notes with and without the embedded derivative, and the fair value of the embedded derivative (in thousands).

		September 30,			December 31,
		2014			2013
	Fair value of Convertible Notes:
	With the embedded derivative	$	18,938		$	15,925
	Without the embedded derivative		18,938			12,455
	Estimated fair value of the embedded derivative	$	-		$	3,470

	Changes in certain inputs into the lattice model can have a significant impact on changes in the estimated fair value of the embedded derivative. For example, the estimated fair value of the embedded derivative will generally decrease with; (1) a decline in the stock price; (2) increases in the estimated stock volatility; and (3) an increase in the estimated credit spread. The changes in the estimated fair value of the embedded derivative during the three and nine months ended September 30, 2014 and 2013 represent unrealized gains, respectively, which have been recorded as gains from change in fair value of embedded derivative in the consolidated statements of operations.
	Derivative Warrant Liability
	In December 2013, the Company sold 21,303,750 common stock units. Each common stock unit consisted of one share of the Company’s common stock and a warrant to purchase one share of the Company’s common stock (the “2013 Warrants”). The agreement governing the 2013 Warrants includes the following terms:
	—	the 2013 Warrants have an exercise price of $1.43 per share, subject to adjustment for certain events, including the issuance of stock dividends on the Company’s common stock and, in certain instances, the issuance of the Company’s common stock or instruments convertible into the Company’s common stock at a price per share less than the exercise price of the 2013 Warrants;
	—	the 2013 Warrants have an expiration date of December 16, 2018;
	—	a holder of 2013 Warrants may exercise the warrants through a cashless exercise if, and only if, the Company does not have an effective registration statement then available for the issuance of the shares of its common stock. If an effective registration statement is available for the issuance of its common stock a holder may only exercise the 2013Warrants through a cash exercise;
	—	the exercise price and the number and type of securities purchasable upon exercise of 2013 Warrants are subject to adjustment upon certain corporate events, including certain combinations, consolidations, liquidations, mergers, recapitalizations, reclassifications, reorganizations, stock dividends and stock splits, a sale of all or substantially all of the Company’s assets and certain other events; and
	—	in the event of an extraordinary transaction (as defined in the 2013 Warrant agreement), generally including any merger with or into another entity, sale of all or substantially all of the Company’s assets, tender offer or exchange offer, or reclassification of its common stock, the Company or any successor entity will pay the 2013 Warrant holder, at such holder’s option, exercisable at any time concurrently with or within 30 days after the consummation of the extraordinary transaction, an amount of cash equal to the value of such holder’s warrants as determined in accordance with the Black Scholes option pricing model and the terms of the 2013 Warrants.
	In August 2014, the Company sold 30,000,000 shares of common stock and warrants to purchase an additional 15,000,000 shares of common stock (the “2014 Warrants”). The agreement governing the 2014 Warrants includes the following terms:
	—	the 2014 Warrants have an exercise price of $0.85 per share, subject to adjustment for certain events, including the issuance of stock dividends on the Company’s common stock and, in certain instances, the issuance of the Company’s common stock or instruments convertible into the Company’s common stock at a price per share less than the exercise price of the 2014 Warrants;
	—	the 2014 Warrants have an expiration date of August 5, 2019;
	—	a holder of the 2014 Warrants may exercise the warrants through a cashless exercise if, and only if, the Company does not have an effective registration statement then available for the issuance of the shares of its common stock. If an effective registration statement is available for the issuance of its common stock a holder may only exercise the 2014 Warrants through a cash exercise;
	—	the exercise price and the number and type of securities purchasable upon exercise of the 2014 Warrants are subject to adjustment upon certain corporate events, including certain combinations, consolidations, liquidations, mergers, recapitalizations, reclassifications, reorganizations, stock dividends and stock splits, a sale of all or substantially all of the Company’s assets and certain other events; and
	—	in the event of an extraordinary transaction (as defined in the 2014 Warrant agreement), generally including any merger with or into another entity, sale of all or substantially all of the Company’s assets, tender offer or exchange offer, or reclassification of its common stock, the Company or any successor entity will pay the 2014 Warrant holder, at such holder’s option, exercisable at any time concurrently with or within 30 days after the consummation of the extraordinary transaction, an amount of cash equal to the value of such holder’s warrants as determined in accordance with the Black Scholes option pricing model and the terms of the 2014 Warrants.
	Based on these terms, the Company has determined that the 2013 Warrants and the 2014 Warrants (together, the “Warrants”) qualify as derivatives and, as such, are presented as derivative warrant liability on the consolidated balance sheets and recorded at fair value each reporting period. The fair value of the Warrants was estimated to be $2.9 million and $7.2 million as of September 30, 2014 and December 31, 2013, respectively. The decrease in the estimated fair value of the Warrants represents an unrealized gain which has been recorded as a gain from the change in fair value of derivative warrant liability in the consolidated statements of operations.

Accounts_Payable_and_Accrued_L

Accounts Payable and Accrued Liabilities	9 Months Ended
Accounts Payable and Accrued Liabilities	Sep. 30, 2014
Payables And Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities	'
	6. Accounts Payable and Accrued Liabilities
	The following table sets forth the components of the Company’s accounts payable and accrued liabilities in the consolidated balance sheets (in thousands).

		September 30,		December 31,
		2014		2013
	Accounts payable — trade	$	2,760	$	6,460
	Accrued legal-related fees		2,237		2,999
	Deferred revenue		-		1,000
	Accrued employee compensation		947		818
	Other accrued liabilities		1,489		1,753
	Total accounts payable and accrued liabilities	$	7,433	$	13,030

Secured_Debt_and_Convertible_N

Secured Debt and Convertible Notes	9 Months Ended
Secured Debt and Convertible Notes	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Senior Secured Debt, Secured Debt and Convertible Notes	'
	7. Senior Secured Debt, Secured Debt and Convertible Notes
	Senior Secured Debt
	In May 2014, the Company entered into a Term Loan Agreement (the “Loan Agreement”) with the lenders party thereto from time to time (each, a “Lender” and collectively, the “Lenders”) and Whitebox Advisors, LLC, as administrative agent for the Lenders (“Whitebox”), with a maturity date of March 15, 2017, pursuant to which the Lenders committed to provide one or more senior secured term loans to the Company in an aggregate amount of up to approximately $31.1 million on the terms and conditions set forth in the Loan Agreement (collectively, the “Term Loan”). The first advance of the Term Loan in the amount of $22.8 million (the “First Advance”), net of discounts and issue costs of $1.6 million and $1.5 million, respectively, was made to the Company in May 2014. Also in May 2014, the Company and its subsidiaries entered into an Exchange and Purchase Agreement (the “Exchange and Purchase Agreement”) with WB Gevo, Ltd. and the other Lenders party thereto from time to time and Whitebox, in its capacity as administrative agent for the Lenders. Pursuant to the terms of the Exchange and Purchase Agreement, the Lenders were given the right, subject to certain conditions, to exchange all or a portion of the outstanding principal amount of the Term Loan for the Company’s newly created 10% Convertible Senior Secured Notes due March 2017 (the “2017 Notes” and, together with the 2022 Notes, the “Convertible Notes”), which are convertible into shares of the Company’s common stock.
	In June 2014, the Lenders exchanged all $25.9 million of outstanding principal amount of Term Loan provided in the First Advance for 2017 Notes, together with accrued paid-in-kind interest of $0.2 million. The terms of the 2017 Notes are set forth in an indenture by and among the Company, its subsidiaries in their capacity as guarantors, and Wilmington Savings Fund Society, FSB, as trustee (the “2017 Notes Indenture”). The 2017 Notes will mature on March 15, 2017. The 2017 Notes have a conversion price (the “Conversion Price”) equal to $1.1584 per share or .8663 shares per $1 principal amount of 2017 Notes. Optional prepayment of the 2017 Notes will not be permitted. The 2017 Notes bear interest at a rate equal to 10% per annum, which is payable 5% in cash and under certain circumstances 5% in kind and capitalized and added to the principal amount of the 2017 Notes. While the 2017 Notes are outstanding, the Company is required to maintain an interest reserve in an amount equal to 10% of the aggregate outstanding principal amount, to be adjusted on an annual basis. As of September 30, 2014, there was a balance of $2.6 million in the interest reserve account. This amount is classified as restricted cash.
	While outstanding, the Term Loan bore an interest rate equal to 15% per annum, of which 5% was payable in cash and 10% was payable in kind and capitalized and added to the principal amount of the Term Loan.
	The 2017 Notes Indenture contains customary affirmative and negative covenants for agreements of this type and events of default, including, restrictions on disposing of certain assets, granting or otherwise allowing the imposition of a lien against certain assets, incurring certain amounts of additional indebtedness, making investments, acquiring or merging with another entity, and making dividends and other restricted payments, unless the Company receives the prior approval of the required holders. The 2017 Notes Indenture also contains limitations on the ability of the holder to assign or otherwise transfer its interest in the 2017 Notes. The 2017 Notes are secured by a lien on substantially all of the assets of the Company and is guaranteed by Agri-Energy and Gevo Development (together, the “Guarantor Subsidiaries” or “Guarantors”). On June 6, 2014, in connection with the issuance of the 2017 Notes, the Company and the Guarantor Subsidiaries entered into a Pledge and Security Agreement in favor of the collateral trustee. The collateral pledged includes substantially all of the assets of the Company and the Guarantor Subsidiaries, including intellectual property and real property. Agri-Energy has also entered into a mortgage with respect to the real property located in Luverne Minnesota.
	The holders of the 2017 Notes may, at any time until the close of business on the business day immediately preceding the maturity date, convert the principal amount of the 2017 Notes, or any portion of such principal amount which is at least $1,000, into shares of the Company’s common stock. Upon conversion of the 2017 Notes, the Company will deliver shares of common stock at an initial conversion rate of 0.8633 shares of common stock per $1.00 principal amount of the 2017 Notes (equivalent to an initial conversion price of approximately $1.1584 per share of common stock). Such conversion rate is subject to adjustment in certain circumstances, including in the event that there is a dividend or distribution paid on shares of the common stock or a subdivision, combination or reclassification of the common stock. The Company also has the right to increase the conversion rate (i) by any amount for a period of at least 20 business days if the Company’s board of directors determines that such increase would be in the Company’s best interest or (ii) to avoid or diminish any income tax to holders of shares of common stock or rights to purchase shares of common stock in connection with any dividend or distribution. In addition, subject to certain conditions described herein, each holder who exercises its option to voluntarily convert its 2017 Notes will receive a make-whole payment in an amount equal to any unpaid interest that would otherwise have been payable on such 2017 Notes through the maturity date (a “Voluntary Conversion Make-Whole Payment”). Subject to certain limitations, we may pay any Voluntary Conversion Make-Whole Payments either in cash or in shares of common stock, at its election.
	Beginning on December 6, 2014, the Company will have the right to require holders of the 2017 Notes to convert all or part of the 2017 Notes into shares of its common stock if the last reported sales price of the common stock over any 10 consecutive trading days equals or exceeds 150% of the applicable conversion price (a “Mandatory Conversion”). Each holder whose 2017 Notes are converted in a Mandatory Conversion will receive a make-whole payment for the converted notes in an amount equal to any unpaid interest that would have otherwise been payable on such 2017 Notes through the maturity date (a “Mandatory Conversion Make-Whole Payment”). Subject to certain limitations, we may pay any Mandatory Conversion Make-Whole Payments either in cash or in shares of common stock, at its election.
	If a fundamental change of the Company occurs, the holders of 2017 Notes may require the Company to repurchase all or a portion of the 2017 Notes at a cash repurchase price equal to 100% of the principal amount of such 2017 Notes, plus accrued and unpaid interest, if any, through, but excluding, the repurchase date, plus a cash make-whole payment for the repurchased 2017 Notes in an amount equal to any unpaid interest that would otherwise have been payable on such convertible 2017 Notes through the maturity date.
	In connection with the transactions described above, the Company also entered into a Registration Rights Agreement, dated May 9, 2014 (the “Registration Rights Agreement”), pursuant to which the Company filed a registration statement on Form S-3 registering the resale of 17.5 million shares of the Company’s common stock which are issuable under the 2017 Notes. This registration statement was declared effective on July 25, 2014. The Company expects to file additional registration statements on Form S-3 or to amend filings in order to register additional shares of common stock of the Company for sale or resale, as necessary in connection with the 2017 Notes.
	The Company has elected the fair value option for accounting of the Term Loan and 2017 Notes in order for management to mitigate income statement volatility caused by measurement basis differences between the embedded instruments or to eliminate complexities of applying certain accounting models. Accordingly, the principal amount of 2017 Notes outstanding at September 30, 2014 of $26.1 million has been recorded at its estimated fair value of $25.6 million and is included in the 2017 Notes recorded at fair value on the consolidated balance sheets at September 30, 2014. Change in the estimated fair value of the 2017 Notes represents an unrealized gain included in gain from change in fair value of 2017 Notes in the consolidated statement of operations. During the three and nine months ended September 30, 2014, the Company incurred cash interest expense of $0.6 million and $0.9 million, respectively, and non-cash paid-in-kind interest expense of $0.2 million, which has been capitalized and included in the principal amount of 2017 Notes as of September 30, 2014.
	The following table sets forth the inputs to the lattice model that were used to value the Term Loan and 2017 Notes for which the fair value option was elected.

		September 30,
		2014
	Stock price	$	0.34
	Conversion Rate		863.3
	Conversion Price	$	1.16
	Maturity date	15-Mar-17
	Risk-free interest rate		0.8	%
	Estimated stock volatility		85	%
	Estimated credit spread		15	%


	The following table sets forth information pertaining to the Term Loan and 2017 Notes which is included in the Company’s consolidated balance sheets (in thousands).


		Principal Amount of Term Loans				Principal Amount of 2017 Notes				Change in Estimated Fair Value				Total
	Balance - December 31, 2013	$	-			$	-			$	-			$	-
	Issuance of Term Loan		25,907				-				-				25,907
	Exchange of Term Loan for 2017 Notes		(25,907	)			25,907				-				-
	Non-cash paid-in-kind interest expense		-				201				-				201
	Gain from change in fair value of debt		-				-				(544	)			(544	)
	Balance - September 30, 2014	$	-			$	26,108			$	(544	)		$	25,564
	Changes in certain inputs into the lattice model can have a significant impact on changes in the estimated fair value of the Term Loan and 2017 Notes. For example, the estimated fair value will generally decrease with; (1) a decline in the stock price; (2) increases in the estimated stock volatility; and (3) an increase in the estimated credit spread. The change in the estimated fair value of the 2017 Notes during the three and nine months ended September 30, 2014, represents an unrealized gain which has been recorded as gain from change in fair value of 2017 Notes in the consolidated statements of operations.

	Secured Debt
	The following table sets forth information pertaining to the Company’s secured debt issued to TriplePoint Capital LLC (“TriplePoint”) which is included in the Company’s consolidated balance sheets (in thousands).

		September 30,				December 31,
		2014				2013
	Secured debt
	TriplePoint - September 2010 Advance	$	-			$	917
	TriplePoint - October 2011 Advance		-				6,657
	TriplePoint - January 2012 Advance		-				3,495
	TriplePoint - May 2014 Advance		897				-
	Total secured debt		897				11,069
	Less:
	Unamortized debt discounts		(58	)			(942	)
			839				10,127
	Less current portion of debt		(253	)			(788	)
	Long-term portion of debt	$	586			$	9,339


	Gevo Loan Agreement. In August 2010, Gevo, Inc. entered into a loan and security agreement (the “Gevo Loan Agreement”) with TriplePoint, pursuant to which the Company borrowed $5.0 million. In July 2012, the Company used $5.4 million of the proceeds from the July 2012 offering of the 2022 Notes to pay in full all amounts outstanding under the Gevo Loan Agreement, including an end-of-term payment equal to 8% of the amount borrowed.
	Original Agri-Energy Loan Agreement. In August 2010, Gevo Development borrowed $12.5 million from TriplePoint to finance its acquisition of Agri-Energy. In September 2010, upon completion of the acquisition, the loan and security agreement (the “Original Agri-Energy Loan Agreement”) was amended to make Agri-Energy the borrower under the facility. In December 2013, the Company used $5.1 million of the proceeds from the offering of common stock units that was completed in December 2013 to pay off the remaining $5.1 million in outstanding principal under this loan.
	Amended Agri-Energy Loan Agreement. In October 2011, the Original Agri-Energy Loan Agreement was amended and restated (the “Amended Agri-Energy Loan Agreement”) to provide Agri-Energy with additional term loan facilities of up to $15.0 million to pay a portion of the costs, expenses, and other amounts associated with the retrofit of the Agri-Energy Facility to produce isobutanol. In October 2011, Agri-Energy borrowed $10.0 million under the additional term loan facilities which bore interest at a rate equal to 11%. In January 2012, Agri-Energy borrowed an additional $5.0 million under the additional term loan facilities, bringing the total borrowed under the additional term loan facilities to $15.0 million. As additional security, concurrently with the execution of the Amended Agri-Energy Loan Agreement, (i) Gevo Development entered into a limited recourse continuing guaranty in favor of TriplePoint, (ii) Gevo Development entered into an amended and restated limited recourse membership interest pledge agreement in favor of TriplePoint, pursuant to which it pledged the membership interests of Agri-Energy as collateral to secure the obligations under its guaranty and (iii) Gevo, Inc. entered into an amendment to its security agreement with TriplePoint (the “Gevo Security Agreement”), which secured its guarantee of Agri-Energy’s obligations under the Amended Agri-Energy Loan Agreement.
	June 2012 Amendments. In June 2012, the Company entered into (i) an amendment (the “Security Agreement Amendment”) to the Gevo Security Agreement and (ii) an amendment (the “Gevo Loan Amendment”) to the Gevo Loan Agreement. In addition, concurrently with the execution of the Security Agreement Amendment and the Gevo Loan Amendment, Agri-Energy entered into an amendment to the Amended Agri-Energy Loan Agreement. These amendments, among other things, permitted the issuance of the 2022 Notes.
	December 2013 Amendments. In December 2013, Gevo, Inc. entered into additional amendments to certain of its existing agreements with TriplePoint to, among other things:
	—	permit the issuance of warrants associated with the Company’s December 2013 offering of common stock units;
	—	waive any prepayment premium (but not any end-of-term payment) with respect to the Original Agri-Energy Loan Agreement and the Amended Agri-Energy Loan Agreement;
	—	expand the events of default to add as an event of default the repurchase of the warrants;
	—	grant TriplePoint a lien and security interest in all of the Intellectual property of the Company;
—	re-price the three outstanding warrants to purchase common stock of the Company that are held by TriplePoint, which as of September 30, 2014 are exercisable in the aggregate for 388,411 shares of the Company’s common stock, to reflect an exercise price equal to $1.18 per share;
—	waive the requirement for Agri-Energy to make principal amortization payments on the Amended Agri-Energy Loan Agreement through December 31, 2014 (the “Restructure Period”);
—	raise the interest rates under the Amended Agri-Energy Loan Agreement to 13% during the Restructure Period (provided that such rate will return to 11% following the Restructure Period so long as no event of default under the Amended Agri-Energy Loan Agreement shall be continuing on the last day of the Restructure Period); and
—	during the period beginning January 2015, and continuing through and including the final monthly installment due under the Amended Agri-Energy Loan Agreement, adjust the monthly payment due and payable to 50% of the fully amortizing amount of principal and interest otherwise due and payable for such month, applied first to outstanding accrued interest and then to principal, with the remaining 50% portion of such required payments of principal and interest for such month accruing and made due and payable at the time of the final monthly installment.
May 2014 Amendments. In May 2014, the Company and its subsidiaries entered into a Consent Under and Third Amendment to Amended and Restated Plain English Growth Capital Loan and Security Agreement and Omnibus Amendment to Loan Documents (the “2014 Amendment”) pursuant to which TriplePoint amended its agreements with the Company and its subsidiaries and consented to (a) the execution, delivery, and performance of the Loan Agreement, the Exchange and Purchase Agreement, the Registration Rights Agreement, the 2017 Notes Indenture, the 2017 Notes, and the other documents related thereto (collectively the “Senior Loan Documents”); (b) the incurrence of the Term Loan with Whitebox and any other indebtedness under the Senior Loan Documents (collectively, the “Senior Indebtedness”); (c) the consummation of the exchange of the Term Loan for the 2017 Notes; (d) the offering, issuance and sale of the 2017 Notes to Whitebox and the conversion of any 2017 Notes into the common stock of the Company pursuant to the terms of the 2017 Notes Indenture; (e) the guaranty of the Senior Indebtedness provided by the Guarantors; (f) the liens granted by each of the Company and the Guarantors to secure the Senior Indebtedness and the other obligations under the Senior Loan Documents; (g) the consummation of any transactions contemplated by, and the terms of, the Senior Loan Documents by the Company and the Guarantors; and (h) the payment and performance of any of the obligations under the Senior Loan Documents by the Company and the Guarantors, including the making of dividends and distributions by the Guarantors to the Company for the purpose of enabling the Company to make any payments under the Senior Loan Documents.
As part of the May 2014 Amendments, the Company repaid $9.6 million in principal payments due under the foregoing loan agreements with TriplePoint and entered into an amended Loan Agreement with TriplePoint. At September 30, 2014, the amended loan agreement had a principal balance of $0.9 million, which amortizes over 36 months and bears interest at a rate equal to 9% per annum and matures in May of 2017. There were no additional concessions or terms of the agreement which would require recognition of a gain or loss due to this amended agreement. As of September 30, 2014, Agri-Energy has granted TriplePoint a junior security interest in all of its assets as security for its obligations under the Amended Agri-Energy Loan Agreement
On July 31, 2014, the Company entered into amendments to the Amended Agri-Energy Loan Agreement and the Gevo Security Agreement to, among other things, permit the offering and issuance of warrants and the incurrence of indebtedness by the Company under such warrants.
2022 Notes
The following table sets forth information pertaining to the 2022 Notes which is included in the Company’s consolidated balance sheets (in thousands).

	Embedded Derivatives				Principal Amount of 2022 Notes				Debt Discount				Total
Balance - December 31, 2012	$	11,000			$	45,000			$	(30,446	)		$	25,554
Amortization of debt discount		-				-				2,780				2,780
Write-off of debt discount associated with conversion of debt		-				-				11,277				11,277
Gain from change in fair value of embedded derivatives		(2,280	)			-				-				(2,280	)
Conversion		(4,416	)			(18,100	)			-				(22,516	)
Balance - September 30, 2013	$	4,304			$	26,900			$	(16,389	)		$	14,815

	Embedded Derivatives				Principal Amount of 2022 Notes				Debt Discount				Total
Balance - December 31, 2013	$	3,470			$	26,900			$	(15,869	)		$	14,501
Amortization of debt discount		-				-				1,889				1,889
Gain from change in fair value of embedded derivatives		(3,470	)			-				-				(3,470	)
Balance - September 30, 2014	$	-			$	26,900			$	(13,980	)		$	12,920

In July 2012, the Company sold $45.0 million in aggregate principal amount of 2022 Notes, with net proceeds of $40.9 million, after accounting for $2.7 million and $1.4 million of discounts and issue costs, respectively. The 2022 Notes bear interest at 7.5% which is to be paid semi-annually in arrears on January 1 and July 1 of each year. The 2022 Notes will mature on July 1, 2022, unless earlier repurchased, redeemed or converted. During the three and nine months ended September 30, 2014, the Company recorded $0.7 million and $2.0 million, respectively, of expense related to the amortization of debt discounts and issue costs and recorded $0.5 million and $1.5 million, respectively, of interest expense related to the 2022 Notes. During the three and nine months ended September 30, 2013, the Company recorded $0.5 million and $2.8 million, respectively, of expense related to the amortization of debt discounts and issue costs and recorded $0.5 million and $1.8 million, respectively, of interest expense related to the 2022 Notes. The amortization of debt issue costs and debt discounts and cash interest are included as a component of interest expense in the consolidated statements of operations. The Company amortizes debt discounts and debt issue costs associated with the 2022 Notes using an effective interest rate of 40% from the issuance date through July 1, 2017, a five-year period, which represents the date the holders can require the Company to repurchase the 2022 Notes.
The 2022 Notes are convertible at an initial conversion rate of 175.6697 shares of the Company’s common stock per $1,000 principal amount of 2022 Notes, subject to adjustment in certain circumstances as described in the Indenture. This is equivalent to an initial conversion price of approximately $5.69 per share of common stock. Holders may convert the 2022 Notes at any time prior to the close of business on the third business day immediately preceding the maturity date of July 1, 2022.
If a holder elects to convert its 2022 Notes prior to July 1, 2017, such holder shall be entitled to receive, in addition to the consideration upon conversion, a Coupon Make-Whole Payment. The Coupon Make-Whole Payment is equal to the sum of the present values of the number of semi-annual interest payments that would have been payable on the 2022 Notes that a holder has elected to convert from the last day through which interest was paid up to but excluding July 1, 2017, computed using a discount rate of 2%. The Company may pay any Coupon Make-Whole Payment either in cash or in shares of common stock at its election. Under the Amended Agri-Energy Loan Agreement with TriplePoint, the Company is prohibited from making any Coupon Make-Whole Payments in cash prior to the payment in full of all remaining outstanding obligations under the Amended Agri-Energy Loan Agreement. If the Company elects to pay in common stock, the stock will be valued at 90% of the average of the daily volume weighted average prices of the Company’s common stock for the 10 trading days preceding the date of conversion. As of September 30, 2014, certain holders of the 2022 Notes had elected to convert notes totaling $18.1 million, reducing the principal balance of the 2022 Notes to $26.9 million. Upon conversion, such 2022 Note holders received 3,179,608 shares of common stock in payment of converted principal of $18.1 million and, pursuant to the terms of the Indenture, such holders also received 2,957,775 shares of common stock in settlement of Coupon Make-Whole Payments of $4.9 million.
If a Make-Whole Fundamental Change (as defined in the Indenture) occurs and a holder elects to convert its 2022 Notes prior to July 1, 2017, the Conversion Rate will increase based upon reference to the table set forth in Schedule A of the Indenture. In no event will the Conversion Rate increase to more than 202.0202 shares of common stock per $1,000 principal amount of 2022 Notes.
If a Fundamental Change (as defined in the Indenture) occurs at any time, then each holder will have the right to require the Company to repurchase all of such holder’s 2022 Notes, or any portion thereof that is an integral multiple of $1,000 principal amount, for cash at a repurchase price of 100% of the principal amount of such 2022 Notes plus any accrued and unpaid interest thereon through, but excluding, the repurchase date. Additionally, on July 1, 2017, each holder will have the right to require the Company to repurchase all of such holder’s 2022 Notes, or any portion thereof that is an integral multiple of $1,000 principal amount, for cash at a repurchase price of 100% of the principal amount of such 2022 Notes plus any accrued and unpaid interest thereon through, but excluding, the repurchase date.
The Company shall have a provisional redemption right (“Provisional Redemption”) to redeem, at its option, all or any part of the 2022 Notes at a price payable in cash, beginning on July 1, 2015 and prior to July 1, 2017, provided that the Company’s common stock for 20 or more trading days in a period of 30 consecutive trading days ending on the trading day immediately prior to the date of the redemption notice exceeds 150% of the Conversion Price in effect on such trading day. On or after July 1, 2017, the Company shall have an optional redemption right (“Optional Redemption”) to redeem, at its option, all or any part of the 2022 Notes at a price payable in cash. The price payable in cash for the Optional Redemption or Provisional Redemption is equal to 100% of the principal amount of 2022 Notes redeemed plus any accrued and unpaid interest thereon through, but excluding, the repurchase date.
If there is an Event of Default (as defined in the Indenture) under the 2022 Notes, the holders of not less than 25% in principal amount of Outstanding Notes (as defined in the Indenture) by notice to the Company and the trustee may, and the trustee at the request of such holders shall, declare the principal amount of all the Outstanding Notes and accrued and unpaid interest thereon to be due and payable immediately.

Significant_Agreements

Significant Agreements	9 Months Ended
Significant Agreements	Sep. 30, 2014
Leases [Abstract]	'
Significant Agreements	'
	8. Significant Agreements
	Off-Take, Distribution and Marketing Agreements
	International Off-Take and Distribution Agreement with Sasol. In July 2011, the Company and Sasol Chemical Industries Limited (“Sasol”) entered into an international off-take agreement to market and distribute renewable isobutanol globally. The agreement had an initial term of three years and appointed Sasol as a non-exclusive distributor of high-purity isobutanol in North and South America and as the exclusive distributor for high-purity isobutanol for solvent and chemical intermediate applications in the rest of the world. This agreement expired in July 2014 and no amounts had been recorded under this agreement as of September 30, 2014.
	Exclusive Supply Agreement with LANXESS. In January 2011, the Company entered into an exclusive supply agreement, as amended, with LANXESS Inc. (“LANXESS”) pursuant to which LANXESS has granted the Company an exclusive first right to supply LANXESS and its affiliates with certain of their requirements for biobased isobutanol during the term of the agreement. The Company’s exclusive first right to supply biobased isobutanol to LANXESS and its affiliates will be subject to the terms of a supply agreement to be mutually agreed upon by the parties at a later date. Additionally, pursuant to the terms of the exclusive supply agreement the Company has granted LANXESS, subject to certain exceptions and conditions, (i) an exclusive first right to acquire its biobased isobutanol to produce isobutylene and butenes for use and sale in the field of chemicals, and (ii) an exclusive right to use the Company’s isobutanol to produce butadiene and isobutylene for use in the production of polybutadiene and butyl rubber. No amounts have been incurred under this agreement as of September 30, 2014.
	Off-Take and Marketing Alliance Agreement and Renewable Fuels Supply Chain Agreement with Mansfield Oil Company. In August 2011, the Company entered into a commercial off-take agreement with Mansfield Oil Company (“Mansfield”), to distribute isobutanol-based fuel into the petroleum market. The agreement allows Mansfield to blend the Company’s isobutanol for its own use, and to be a distributor of the Company’s isobutanol for a term of five years. The Company also entered into a three--year supply services agreement with C&N, a Mansfield subsidiary (“C&N”), which will provide supply chain services including logistics management, customer service support, invoicing and billing services. No amounts have been recorded under these agreements as of September 30, 2014.
	Ethanol Marketing Agreement with C&N, a subsidiary of Mansfield Oil Company. Substantially all ethanol sold by Agri-Energy from the date of acquisition through December 31, 2012 and during the three and nine months ended September 30, 2014 was sold to C&N pursuant to an ethanol purchase and marketing agreement. The Company did not sell any ethanol during the three or nine months ended September 30, 2013. The ethanol purchase and marketing agreement with C&N was entered into on April 1, 2009 and automatically renews for subsequent one-year terms unless either party terminates the agreement 60 days before the end of a term. Under the terms of the agreement, C&N will market substantially all of Agri-Energy’s ethanol production from the Agri-Energy Facility and will pay to Agri-Energy the gross sales price paid by the end customer less expenses and a marketing fee.
	Jet Fuel Supply Agreements with the Defense Logistics Agency (U.S. Air Force, U.S. Army and U.S. Navy). During September 2011, the Company was awarded a contract for the procurement of up to 11,000 gallons of alcohol-to-jet (ATJ) fuel for the purposes of certification and testing by the U.S. Air Force. The term of the agreement was through December 30, 2012. In September 2012, the Company was awarded an additional contract by the U.S. Air Force for the procurement of up to 45,000 gallons of biojet fuel. In March 2013, the Company entered into a contract with the Defense Logistics Agency to supply the U.S. Army with 3,650 gallons of biojet fuel and in May 2013 this initial order was increased by 12,500 gallons. In September 2013, the Company entered into a contract with the Defense Logistics Agency to supply the U.S. Navy with 20,000 gallons of biojet fuel. During the three and nine months ended September 30, 2014, the Company recorded $0.8 million and $1.6 million, respectively, of revenue associated with shipments of biojet fuel under these contracts. During the three and nine months ended September 30, 2013, the Company recorded $0.4 million and $1.1 million, respectively, of revenue associated with shipments of biojet fuel under these contracts.
	Commercialization and Development Agreements
	Development and Commercialization Agreements with ICM, Inc. In October 2008, the Company signed development and commercialization agreements with ICM, Inc. (“ICM”).
	Under the terms of the development agreement, the Company performed commercial-scale isobutanol production trials in ICM’s research plant and facility in St. Joseph, Missouri, the demonstration plant. The Company was required to pay for or reimburse ICM for engineering fees, equipment, plant modification costs, project fees and various operating expenses. In December 2011, the development agreement was amended to extend the term indefinitely. The development agreement, as amended, may be cancelled by either party with 30 days’ prior written notice. The Company did not incur any costs relating to the demonstration plant during the nine months ended September 30, 2014 or 2013.
	The commercialization agreement, which was amended and restated in August 2011, is effective through October 2018, and outlines the terms and fees under which ICM acts as the Company’s exclusive provider of certain engineering and construction services. Also, under the commercialization agreement, the Company is ICM’s exclusive technology partner for the production of butanols, pentanols and propanols from the fermentation of sugars.
	The Company has also engaged ICM to perform engineering studies, plant evaluations and other services. In August 2011, the Company entered into a work agreement with ICM whereby ICM will provide engineering, procurement and construction services for the retrofit of ethanol plants.
	Joint Research, Development, License and Commercialization Agreement with The Coca-Cola Company. During November 2011, the Company entered into a joint research, development, license and commercialization agreement with The Coca-Cola Company (“Coca-Cola”). During the first two years of the agreement, Coca-Cola agreed to pay the Company a fixed price fee for a research program outlined in the agreement. The Company recognizes these fees as revenue over the performance period. The payments received are not refundable. The Company did not recognize revenue under this agreement during the three and nine months ended September 30, 2014 and recognized $0.3 million and $0.9 million, during the three and nine months ended September 30, 2013, respectively.
	License Agreement
	License Agreement with Cargill, Incorporated. In February 2009, the Company entered into a license agreement with Cargill, Incorporated (“Cargill”) to obtain certain biological materials and license patent rights to use a biocatalyst owned by Cargill. Under the license agreement, Cargill has granted the Company an exclusive, royalty-bearing license, with limited rights to sublicense, to use the patent rights in a certain field, as defined in the license agreement.
	The license agreement contains five milestone payments totaling approximately $4.3 million that are payable by the Company after each milestone is completed. During 2009, two milestones were completed and the Company recorded the related milestone amounts, along with an up-front signing fee, totaling $0.9 million, to research and development expense. During March 2010, the Company completed milestone number three and recorded the related milestone amount of $2.0 million to research and development expense at its then-current present value of $1.6 million because the milestone payment was paid over a period greater than 12 months from the date that it was incurred. As of December 2012, the Company had not completed milestone number four. However, under the terms of the agreement, the Company was entitled to pay a $0.5 million license fee in lieu of completing milestone number four. This fee was paid in March 2013 through the issuance of 250,000 shares of the Company’s common stock to Cargill. Milestone number five included in the license agreement representing potential payments of up to $1.0 million, which is due by December 2015, has not been met as of September 30, 2014 and no amount has been recorded as a liability for this milestone.
	Upon commercialization of a product which uses Cargill’s biological material or is otherwise covered by the patent rights under the license agreement, a royalty based on net sales is payable by the Company, subject to a minimum royalty amount per year, as defined in the license agreement, and up to a maximum amount per year.
	The license agreement provides an option for Cargill to purchase a nonexclusive, royalty-bearing license for the use of a Company biocatalyst that utilizes the Cargill biological material or licensed patents for a royalty rate equal to the lowest rate offered to any third party.
	The Company may terminate the license agreement at any time upon 90 days’ prior written notice. Unless terminated earlier, the license agreement remains in effect until the later of December 31, 2025 and the date that no licensed patent rights remain.
	Other
	In June 2011, the Company announced that it had successfully produced fully renewable and recyclable polyethylene terephthalate (“PET”) in cooperation with Toray Industries, Inc. (“Toray Industries”). Working directly with Toray Industries, the Company employed prototypes of commercial operations from the petrochemical and refining industries to make para-xylene from isobutanol. Toray Industries used the Company’s bio-para-xylene (“bio-PX”) and commercially available renewable mono ethylene glycol to produce fully renewable PET films and fibers. In June 2012, the Company entered into a definitive agreement with Toray Industries, as amended in October 2013, for the joint development of an integrated supply chain for the production of bio-PET. Pursuant to the terms of the agreement with Toray Industries, the Company received $1.0 million which was used by the Company for the design and construction of a demonstration plant. In May 2014, the Company successfully shipped the requisite volumes of bio-PX associated with its contract with Toray Industries and, as a result, the Company recognized the $1.0 million, as well as revenue associated with the sale of the bio-PX, as a component of hydrocarbon revenue during the three months ended June 30, 2014. At December 31, 2013, the Company included the $1.0 million as a component of accounts payable and accrued liabilities in its consolidated balance sheets.
	Within its research and development activities, the Company routinely enters into research and license agreements with various entities. Future royalty payments may apply under these license agreements if the technologies are used in future commercial products. In addition, the Company may from time to time make gifts to universities and other organizations to expand research activities in its fields of interest. Any amounts paid under these agreements are generally recorded as research and development expenses as incurred.
	The Company has been awarded grants or cooperative agreements from a number of government agencies, including the U.S. Department of Energy, U.S. National Science Foundation, U.S. Environmental Protection Agency, Army Research Labs and the U.S. Department of Agriculture. Revenues recorded related to these grants and cooperative agreements are recorded within grant and other revenue in the Company’s consolidated statements of operations.

Gevo_Development

Gevo Development	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Gevo Development	'
	9. Gevo Development
	Gevo, Inc. formed Gevo Development in September 2009 to finance and develop biorefineries through joint venture, tolling arrangements or direct acquisition. Biorefinery plants accessed through Gevo Development are intended to be retrofitted using Gevo, Inc.’s integrated fermentation technology to produce isobutanol.
	Gevo, Inc. currently owns 100% of the outstanding equity interests of Gevo Development as a wholly owned subsidiary. Gevo Development has two classes of membership interests outstanding. Gevo, Inc. is the sole owner of the class A interests. Prior to September 2010, CDP Gevo, LLC (“CDP”), was the sole owner of the class B interests, which comprise 10% of the outstanding equity interests of Gevo Development. In September 2010, Gevo, Inc. became the sole owner of Gevo Development by acquiring 100% of the class B interests in Gevo Development from CDP pursuant to an equity purchase agreement. In exchange for the class B interests, CDP received aggregate consideration of $1.1 million.
	The original issuance of the class B interests was considered to be a grant of non-employee stock-based compensation. As vesting of the awards was dependent on counterparty performance conditions (the acquisition and retrofit of a biorefinery plant), no compensation expense had been recorded prior to September 2010 because the lowest aggregate fair value of the awards was zero. Upon the purchase of the class B interests in September 2010, the Company recorded stock-based compensation of $0.8 million, which reflected the amount paid during 2010 for the class B interests that was not dependent on counterparty performance. The final payment of $0.1 million made in January 2012 was dependent on the continued employment of the two co-managing directors of Gevo Development. The employment of the co-managing directors was terminated effective March 2012 (as discussed in more detail below).
	Gevo, Inc. made capital contributions to Gevo Development of $1.6 million and $24.7 million during the three and nine months ended September 30, 2014, respectively, and $7.0 million and $14.1 million during the three and nine months ended September 30, 2013, respectively.
	The following table sets forth (in thousands) the net loss incurred by Gevo Development (including Agri-Energy after September 22, 2010, the closing date of the acquisition) which has been fully allocated to Gevo, Inc.’s capital contribution account based upon its capital contributions (for the period prior to September 2010) and 100% ownership (for the period after September 22, 2010).

		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Gevo Development Net Loss	$	(2,808	)	$	(5,559	)	$	(12,411	)	$	(12,862	)
	In connection with the formation of Gevo Development in September 2009, the Company granted CDP a warrant to purchase 858,000 shares of the Company’s common stock. The warrant has an exercise price of $2.70 per share which represented the estimated fair value of Gevo, Inc.’s common stock on the date of grant. The warrant expires in September 2016, unless terminated earlier as provided in the agreement.
	In September 2010, the beneficial owners of the equity interests of CDP became employees of Gevo, Inc. and the warrant agreement was amended and restated to provide that 50% of the warrant shares granted under such warrant agreement would vest in September 2010. The remaining warrant shares were to vest over a two-year period beginning in September 2010, subject to acceleration and termination in certain circumstances. The Company valued the warrant shares at $14.0 million. Effective March 23, 2012, the employment of the beneficial owners of CDP was terminated. Pursuant to the terms of the warrant agreement, all unvested warrant shares became immediately vested and, as such, the Company recorded $2.6 million of stock-based compensation expense during 2012.
	Since its formation, Gevo Development has been and continues to be considered a variable interest entity. Gevo, Inc., the primary beneficiary of Gevo Development, has both (i) the power to direct the activities of Gevo Development that most significantly impact Gevo Development’s economic performance and (ii) the obligation to absorb losses of Gevo Development that could potentially be significant to Gevo Development or the right to receive benefits from Gevo Development that could potentially be significant to Gevo Development. As such, Gevo Development is consolidated. The accounts of Agri-Energy are consolidated within Gevo Development as a wholly owned subsidiary. As of September 30, 2014 and December 31, 2013, Gevo Development does not have any assets that can be used only to settle obligations of Gevo Development. However, as of September 30, 2014 under the terms of the Amended Agri-Energy Loan Agreement with TriplePoint, as amended, subject to certain limited exceptions, Agri-Energy is only permitted to pay dividends if all principal balances due to TriplePoint have been paid. No gain or loss was recognized by the Company upon the initial consolidation of Gevo Development.

Redfield_Energy_LLC

Redfield Energy, LLC	9 Months Ended
Redfield Energy, LLC	Sep. 30, 2014
Equity Method Investments And Joint Ventures [Abstract]	'
Redfield Energy, LLC	'
	10. Redfield Energy, LLC
	In June 2011, Gevo Development entered into an isobutanol joint venture agreement (the “Joint Venture Agreement”) with Redfield Energy, LLC, a South Dakota limited liability company (“Redfield”), and executed the second amended and restated operating agreement of Redfield (together with the Joint Venture Agreement, the “Joint Venture Documents”). Under the terms of the Joint Venture Documents, Gevo Development and Redfield have agreed to work together to retrofit Redfield’s approximately 50 million gallon per year ethanol production facility located near Redfield, South Dakota (the “Redfield Facility”) for the commercial production of isobutanol. Under the terms of the Joint Venture Agreement, Redfield has issued 100 Class G membership units in Redfield (the “Class G Units”) to Gevo Development. Gevo Development is the sole holder of Class G units, which entitle Gevo Development to certain information and governance rights with respect to Redfield, including the right to appoint two members of Redfield’s 11-member board of managers. The Class G units currently carry no interest in the allocation of profits, losses or other distributions of Redfield and no voting rights. Such rights will vest upon the commencement of commercial isobutanol production at the Redfield Facility, at which time Gevo Development anticipates consolidating Redfield’s operations because Gevo anticipates it will control the activities that are most significant to the entity.
	Gevo Development will be responsible for all costs associated with the retrofit of the Redfield Facility. Redfield will remain responsible for certain expenses incurred by the facility including certain repair and maintenance expenses and any costs necessary to ensure that the facility is in compliance with applicable environmental laws. The Company anticipates that the Redfield Facility will continue its current ethanol production activities during much of the retrofit. Once the retrofit assets have been installed, the ethanol production operations will be suspended to enable testing of the isobutanol production capabilities of the facility (the “Performance Testing Phase”). During the Performance Testing Phase, Gevo Development will be entitled to receive all revenue generated by the Redfield Facility and will make payments to Redfield to cover the costs incurred by Redfield to operate the facility plus the profits, if any, that Redfield would have received if the facility had been producing ethanol during that period (the “Facility Payments”). Gevo Development has also agreed to maintain an escrow fund during the Performance Testing Phase as security for its obligation to make the Facility Payments.
	If certain conditions are met, commercial production of isobutanol at the Redfield Facility will begin upon the earlier of the date upon which certain production targets have been met or the date upon which the parties mutually agree that commercial isobutanol production at the Redfield Facility will be commercially viable at the then-current production rate. At that time, (i) Gevo Development will have the right to appoint a total of four members of Redfield’s 11-member board of managers, and (ii) the voting and economic interests of the Class G units will vest and Gevo Development, as the sole holder of the Class G Units, will be entitled to a percentage of Redfield’s profits, losses and distributions, to be calculated based upon the demonstrated isobutanol production capabilities of the Redfield Facility.
	Gevo Development, or one of its affiliates, will be the exclusive marketer of all products produced by the Redfield Facility once commercial production of isobutanol has begun. Additionally, Gevo, Inc. will license the technology necessary to produce isobutanol at the Redfield Facility to Redfield, subject to the continuation of the marketing arrangement described above. In the event that the isobutanol production technology fails or Redfield is permanently prohibited from using such technology, Gevo Development will forfeit the Class G Units and lose the value of its investment in Redfield.
	Gevo, Inc. entered into a guaranty effective June 2011, pursuant to which it has unconditionally and irrevocably guaranteed the payment by Gevo Development of any and all amounts owed by Gevo Development pursuant to the terms and conditions of the Joint Venture Agreement and certain other agreements that Gevo Development and Redfield expect to enter into in connection with the retrofit of the Redfield Facility.
	As of September 30, 2014, the Company has incurred $0.4 million in preliminary project engineering and permitting process costs for the future retrofit of the Redfield Facility which have been recorded on the Company’s consolidated balance sheets in deposits and other assets.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2014
Share Based Compensation [Abstract]	'
Stock-Based Compensation	'
	11. Stock-Based Compensation
	The Company records expense during the vesting period for share-based payment awards granted to employees and non-employees.
	The following table sets forth the Company’s stock-based compensation expense (in thousands) for the periods indicated.

		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Stock options and employee stock purchase plan awards
	Research and development	$	96	$	172	$	355	$	507
	Selling, general and administrative		225		411		764		1,499

	Restricted stock awards
	Research and development		90		-		361		-
	Selling, general and administrative		448		374		882		1,038

	Warrants issued
	Selling, general and administrative		-		-		-		39
	Non-cash stock-based compensation		859		957		2,362		3,083

	Modified stock option awards
	Selling, general and administrative		-		-		-		-

	Purchase of Class B interests of Gevo Development from CDP for cash
	Selling, general and administrative		-		-		-		-
	Cash stock-based compensation		-		-		-		-

	Total stock-based compensation	$	859	$	957	$	2,362	$	3,083

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	12. Commitments and Contingencies
	Legal Matters. On January 14, 2011, Butamax filed a complaint (the “Complaint”) in the United States District Court for the District of Delaware (“Delaware District Court”), as Case No. 1:11-cv-00054-SLR, alleging that the Company is infringing one or more claims made in U.S. Patent No. 7,851,188 (the “’188 Patent”), entitled “Fermentive Production of Four Carbon Alcohols.” The ’188 Patent, which has been assigned to Butamax, claims certain recombinant microbial host cells that produce isobutanol and methods for the production of isobutanol using such host cells. Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. On March 25, 2011, the Company filed a response to the Complaint, denying Butamax’s allegations of infringement and raising affirmative defenses.
	On August 11, 2011, Butamax amended the Complaint to include allegations that the Company is infringing one or more claims made in U.S. Patent No. 7,993,889 (the “’889 Patent”), also entitled “Fermentive Production of Four Carbon Alcohols” (the “Amended Complaint”). The ’889 Patent, which has been assigned to Butamax, claims methods for producing isobutanol using certain recombinant yeast microorganisms expressing an engineered isobutanol biosynthetic pathway. The Company believes that the Amended Complaint is without merit and will continue to aggressively defend its freedom to operate.
	On September 13, 2011, the Company filed an answer to the Amended Complaint in which it asserted counterclaims against Butamax and DuPont for infringement of U.S. Patent No. 8,017,375 (the “’375 Patent”), entitled “Yeast Organism Producing Isobutanol at a High Yield” and U.S. Patent No. 8,017,376 (the “’376 Patent”), entitled “Methods of Increasing Dihydroxy Acid Dehydratase Activity to Improve Production of Fuels, Chemicals, and Amino Acids.” The counterclaims sought a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. These counterclaims were set for trial in August 2013. On July 26, 2013, the Delaware District Court issued an order regarding claim construction and summary judgment of the Company’s counterclaims involving the ’375 and ’376 Patents. Both parties had asked the Delaware District Court to resolve certain issues regarding the ’375 and ’376 Patents without a trial by seeking summary judgment from the Delaware District Court. Butamax had filed motions seeking summary judgment that it did not infringe such patents and the Delaware District Court granted Butamax’s motions on this issue. Butamax had also moved for summary judgment of invalidity on both patents. The Delaware District Court granted Butamax’s motion of invalidity on the ’375 Patent, but denied Butamax’s motion of invalidity on the ’376 Patent. On August 8, 2013, an order was issued by the Delaware District Court which entered a final judgment of non-infringement in favor of Butamax and DuPont with respect to the claims of the ’375 and ’376 Patents. The August 8, 2013 order also entered a final judgment of invalidity in favor of Butamax and DuPont with respect to the claims of the ’375 Patent. In addition, it was further ordered that the Butamax and DuPont claims and counterclaims relating to the unenforceability of the ’375 Patent, and the invalidity and/or unenforceability of the ’376 Patent, would be dismissed without prejudice, and that the Butamax and DuPont claims for exceptional case, attorney’s fees and/or costs would be preserved for later presentation to the Delaware District Court. As a result of the August 8, 2013 order, a trial did not occur on August 12, 2013 as previously scheduled. On August 26, 2014, Butamax and DuPont’s claims for exceptional case, attorney’s fees and/or costs were denied.
	On September 22, 2011, Butamax filed a motion for preliminary injunction with respect to the alleged infringement by the Company of one or more claims made in the ’889 Patent.
	On January 24, 2012, the Company filed a complaint in the Delaware District Court, as Case No. 1:12-cv-00070-SLR, alleging that Butamax and DuPont are infringing one or more claims made in U.S. Patent No. 8,101,808 (the “’808 Patent”) entitled “Recovery of Higher Alcohols from Dilute Aqueous Solutions.” The ’808 Patent claims methods to produce a C3-C6 alcohol—for example, isobutanol—through fermentation and to recover that alcohol from the fermentation medium. The Company sought a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. On May 8, 2013, the Company stipulated and agreed to dismiss without prejudice the ’808 Patent suit against Butamax, DuPont, or their affiliates, with each side bearing its own costs and fees in the action. The Company and Butamax further stipulated and agreed that the Company shall not re-assert the ’808 Patent against Butamax, DuPont, or their affiliates until a final Certificate of Reexamination is received from the U.S. Patent and Trademark Office (“USPTO”) in Inter Partes Reexamination Control No. 95/000,666.
	On March 12, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-00298-SLR, alleging that the Company is infringing one or more claims made in U.S. Patent No. 8,129,162, entitled “Ketol-Acid Reductoisomerase Using NADH.” This complaint is in addition to the Amended Complaint discussed above. Butamax is seeking a declaratory judgment, injunctive relief, damages, interest, costs and expenses, including attorney’s fees. The Company believes that it has meritorious defenses to these claims and intends to vigorously defend this lawsuit. This case is scheduled for trial on April 25, 2016.
	On March 13, 2012, the Company filed a complaint in the Delaware District Court, as Case No. 1:12-cv-00301-SLR, alleging that Butamax and DuPont are infringing U.S. Patent No. 8,133,715 (the “’715 Patent”), entitled “Reduced By-Product Accumulation for Improved Production of Isobutanol.” The ’715 Patent claims recombinant microorganisms, including yeast, with modifications for the improved production of isobutanol. The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses.
	On April 10, 2012, the Company filed a complaint (the “Gevo Complaint”) in the Delaware District Court, as Case No. 1:12-cv-00448-SLR, alleging that Butamax and DuPont are infringing one or more claims made in U.S. Patent No. 8,153,415 (the “’415 Patent”) entitled “Reduced By-Product Accumulation for Improved Production of Isobutanol.” The ’415 Patent claims technology which eliminates two pathways that compete for isobutanol pathway intermediates in yeast. The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses.
	On April 17, 2012, the Company amended the Gevo Complaint to include allegations that Butamax and DuPont are infringing one or more claims made in U.S. Patent No. 8,158,404 (the “’404 Patent”) entitled “Reduced By-Product Accumulation for Improved Production of Isobutanol.” The ’404 Patent claims the reduction or elimination of important enzymes in a pathway in isobutanol- producing yeast. The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses.
	On May 9, 2012, coordinated discovery was ordered for Case Nos. 1:12-cv-00070-SLR, 1:12-cv-00298-SLR, 1:12-cv-00301-SLR, and 1:12-cv-00448-SLR. By virtue of the same order, discovery in Case No. 1:12-cv-00602-SLR was also coordinated with these cases.
	On May 15, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-00602-SLR, alleging that the Company is infringing one or more claims made in U.S. Patent No. 8,178,328, entitled “Fermentive Production of Four Carbon Alcohols.” Butamax is seeking a declaratory judgment, injunctive relief, damages, interest, costs and expenses, including attorney’s fees. The Company believes that it has meritorious defenses to these claims and intends to vigorously defend this lawsuit. This case is scheduled for trial on April 25, 2016.
	On June 19, 2012, the Delaware District Court denied the motion for preliminary injunction which was filed by Butamax on September 22, 2011 with respect to the alleged infringement by the Company of one or more claims made in the ’889 Patent. As is normal and customary in patent infringement actions of this nature, Butamax then filed a notice of appeal. In connection with their appeal, Butamax also filed a motion with the Delaware District Court seeking a temporary order to limit the Company’s activities with respect to the automotive fuel blending market while Butamax appealed the denial of its motion for preliminary injunction.
	On July 6, 2012, the Delaware District Court issued a temporary order which stated, in part, that the Company could not deliver, provide, distribute, ship, release or transfer in any way bio-isobutanol produced at the Agri-Energy Facility to any third party for any use or purpose related to the automotive fuel blending market while Butamax appealed the denial of its motion for preliminary injunction. The Company filed an appeal of the temporary order. Under the temporary order, the Company remained free to operate in markets such as chemicals, jet fuel, marine fuel and small engine fuel. On August 10, 2012, the Federal Circuit Court of Appeals granted the Company’s motion to stay the status quo order entered on July 6, 2012 by the Delaware District Court. On November 16, 2012, the Federal Circuit Court of Appeals affirmed the Delaware District Court’s denial of Butamax’s preliminary injunction motion.
	On July 31, 2012, the Company filed a complaint in the United States District Court for the Eastern District of Texas, as Case No. 2:12-cv-00417, alleging that Butamax, DuPont, BP p.l.c., BP Corporation North America Inc. and BP Biofuels North America LLC are infringing U.S. Patent No. 8,232,089 (the “’089 Patent), entitled “Cytosolic Isobutanol Pathway Localization for the Production of Isobutanol.” The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. On December 17, 2012, this case was transferred to the Delaware District Court as Case No. 1:12-cv-01724-SLR. On February 19, 2013, BP p.l.c. filed a motion seeking to dismiss the Company’s complaint for failure to state a claim against it. On March 8, 2013, the Company filed a response in opposition to BP p.l.c.’s motion. On March 18, 2013, BP p.l.c. filed its reply brief, and the issue was submitted to the court for decision. On July 8, 2013, the court granted BP p.l.c.’s motion. Despite the court’s decision, Butamax, DuPont, BP Corporation North America Inc. and BP Biofuels North America LLC remain defendants in the suit.
	On July 31, 2012, Butamax and DuPont filed a lawsuit in the Delaware District Court for declaratory judgment against the Company, as Case No. 1:12-cv-00999-SLR, seeking a judicial determination that the ’089 Patent is invalid and that Butamax and DuPont do not infringe it. On January 28, 2013, this case was closed following a voluntary stipulation of dismissal filed by both parties.
	On August 6, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01014-SLR, alleging that the Company is infringing U.S. Patent No. 8,222,017, entitled “Ketol-Acid Reductoisomerase Using NADH.” Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. This case is scheduled for trial on April 25, 2016. On January 22, 2013, discovery in this case was consolidated with Case Nos. 1:12-cv-00070-SLR, 1:12-cv-00298-SLR, 1:12-cv-00301-SLR, 1:12-cv-00448-SLR, and 1:12-cv-00602-SLR. In December 2013, Gevo withdrew claims of infringement against Butamax in Case Nos. 1:12-cv-00301-SLR, and 1:12-cv-00448-SLR. Despite the withdrawal of the infringement claims by Gevo against Butamax in Case Nos. 1:12-cv-00301-SLR and 1:12-cv-00448-SLR, Butamax continues to pursue counterclaims of invalidity in these cases.
	On August 14, 2012, the Company filed a lawsuit in the United States District Court for the Eastern District of Texas for declaratory judgment against Butamax, DuPont, BP p.l.c., BP Corporation North America Inc. and BP Biofuels North America LLC, as Case No. 2:12-cv-00435, seeking a judicial determination that a recently issued Butamax U.S. Patent No. 8,241,878 (the “’878 Patent”), entitled “Recombinant Yeast Host Cell with Fe-S Cluster Proteins and Methods of Using Thereof” is invalid and that the Company does not infringe it. On December 17, 2012, this case was transferred to the Delaware District Court as Case No. 1:12-cv-01725-SLR. On January 28, 2013, this case was closed following a voluntary stipulation of dismissal filed by both parties.
	On August 14, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01036-SLR, alleging that the Company is infringing the ’878 Patent. Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. This case is scheduled for trial on August 24, 2015.
	On September 25, 2012, the Company filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01202-SLR, alleging that Butamax and DuPont are infringing U.S. Patent No. 8,273,565 (the “’565 Patent”), entitled “Methods of Increasing Dihydroxy Acid Dehydratase Activity to Improve Production of Fuels, Chemicals, and Amino Acids.” The Company is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. On September 25, 2012, Butamax and DuPont filed a lawsuit in the Delaware District Court for declaratory judgment against the Company, as Case No. 1:12-cv-01201-SLR, seeking a judicial determination that the ’565 Patent is invalid and that Butamax and DuPont do not infringe it. On August 9, 2013, Case Nos. 1:12-cv-01202-SLR and 1:12-cv-01201-SLR were closed following a voluntary stipulation of dismissal filed by both parties.
	On September 25, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01200-SLR, alleging that the Company is infringing U.S. Patent No. 8,273,558, entitled “Fermentive Production of Four Carbon Alcohols.” Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. This case is scheduled for trial on August 24, 2015.
	On October 8, 2012, Butamax filed a complaint in the Delaware District Court, as Case No. 1:12-cv-01300-SLR, alleging that the Company is infringing U.S. Patent No. 8,283,144, entitled “Fermentive Production of Four Carbon Alcohols.” Butamax is seeking a declaratory judgment, injunctive relief, damages and costs, including attorney’s fees and expenses. This case is scheduled for trial on August 24, 2015.
	On October 8, 2012, Butamax filed a lawsuit in the Delaware District Court for declaratory judgment against the Company, as Case No. 1:12-cv-01301-SLR, seeking a judicial determination that Butamax is not infringing the Company’s U.S. Patent No. 8,283,505, entitled “Recovery of Higher Alcohols from Dilute Aqueous Solutions.” On January 28, 2014 the Delaware District Court issued an order dismissing Case No. 1:12-cv-01301-SLR.
	On February 13, 2013, coordinated discovery was ordered for Case Nos. 1:12-cv-01036-SLR, 1:12-cv-01200-SLR, 1:12-cv-01201-SLR, 1:12-cv-01202-SLR, 1:12-cv-01300-SLR, 1:12-cv-01301-SLR, and 1:12-cv-01724-SLR. Case Nos. 1:12-cv-01036-SLR, 1:12-cv-01200-SLR and 1:12-cv-01300-SLR are currently set for trial on August 24, 2015.
	On March 19, 2013, the Delaware District Court issued an order regarding claim construction and summary judgment in the patent suit involving the ’188 Patent and the ’889 Patent. Both parties had asked the Delaware District Court to resolve certain issues regarding the ’188 Patent and the ’889 Patent without a trial by seeking summary judgment from the court. Butamax had filed a motion seeking summary judgment that the Company infringed such patents, but the Delaware District Court denied Butamax’s motion. The Company moved for summary judgment of noninfringement, both as a matter of literal infringement and infringement under the doctrine of equivalents, and the court granted the Company’s motion regarding doctrine of equivalents infringement. The Company also moved for summary judgment of invalidity of various claims in the ’188 Patent and the ’889 Patent. The Delaware District Court granted this motion in part, ruling that Butamax’s claims related to the inactivation of competing pathways for carbon flow were invalid.
	The Delaware District Court also provided certain claim construction rulings, including a ruling that Butamax’s patent claims were limited to an “acetohydroxy acid isomeroreductase” enzyme that is “NADPH-dependent.” The remaining issues were to be resolved by a jury trial, scheduled to commence on April 1, 2013.
	On March 20, 2013, the Delaware District Court held the final pre-trial hearing leading up to the trial on the ’188 Patent and the ’889 Patent scheduled to commence April 1, 2013. During the hearing, Butamax’s attorney acknowledged that the Company does not infringe such patents under the Delaware District Court’s construction of a key claim term in such patents, “acetohydroxy acid isomeroreductase.” Butamax offered to stipulate to no literal infringement under the Delaware District Court’s construction. In view of this stipulation and the court’s prior ruling of no infringement under Butamax’s alternative infringement theory, the doctrine of equivalents, on April 10, 2013 a judgment of no infringement was entered in favor of the Company.
	On April 19, 2013, Butamax filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit to appeal the Delaware District Court’s Memorandum and Order of March 19, 2013, and the Delaware District Court’s Amended Final Judgment of April 10, 2013. Oral arguments for the Butamax appeal were heard by the U.S. Court of Appeals for the Federal Circuit on November 7, 2013.
	On February 18, 2014, the U.S. Court of Appeals for the Federal Circuit vacated the Delaware District Court’s denial of Butamax’s motion for summary judgment of literal infringement of the asserted claims of the ’188 Patent and the ’889 Patent and remanded the question of infringement to the Delaware District Court for reconsideration under a revised claim construction. The U.S. Court of Appeals for the Federal Circuit also vacated and remanded the Delaware District Court’s grant of Gevo’s motion for summary judgment of noninfringement under the doctrine of equivalents. The U.S. Court of Appeals for the Federal Circuit also reversed the Delaware District Court’s grant of Gevo’s motion for summary judgment of invalidity for lack of a written description of claims 12 and 13 of the ’889 Patent and the Delaware District Court’s order that those same claims are invalid for lack of enablement. The remanded trial for the ’188 and ’889 patents in the Delaware District Court was scheduled to be held on July 21, 2014. On April 22, 2014, the Company filed a Petition for Writ of Certiorari with the Supreme Court of the United States to appeal the Federal Circuit Court’s decision. On April 25, 2014, the Company filed a motion to stay the Delaware District Court’s July 21, 2014 trial pending the disposition of the Company’s Petition for Writ of Certiorari with the Supreme Court of the United States and any follow-on proceedings. On July 11, 2014, the US District Court of Delaware granted Gevo’s motion to stay the patent litigation on the ‘188 and ‘889 Patents. The District Court’s decision postpones the trial in this action, which was scheduled to begin on July 21, 2014. The decision by the District Court was based on the status of Gevo’s petition for a writ of certiorari in the United States Supreme Court. The Supreme Court has neither granted nor denied Gevo’s petition, but appears to be holding the petition pending its decision in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., a case that could change the Federal Circuit’s standard of review of district court claim construction, and could ultimately negate any jury verdict obtained under the current interpretation of the patent claims. Oral argument in Teva occurred on October 15, 2014 and an opinion from the Supreme Court is anticipated in the spring of 2015.
	On February 18, 2014, the Delaware District Court granted Gevo’s motion to stay the litigation regarding Gevo’s ’715 Patent, ’404 Patent and ’415 Patent pending the USPTO’s issuance of a Right to Appeal Notice during inter partes re-examination of those patents.
	A mediation session between Gevo and Butamax occurred on June 5, 2014.
	Due to the nature and stage of this litigation, the Company has determined that the possible loss or range of loss related to this litigation cannot be reasonably estimated at this time. The next Delaware District Court trial for the Butamax litigation is currently scheduled for August 24, 2015. The Company expects to continue to incur significant costs related to its involvement in the foregoing legal proceedings.
	Indemnifications. In the ordinary course of its business, the Company makes certain indemnities under which it may be required to make payments in relation to certain transactions. As of September 30, 2014 and December 31, 2013, the Company did not have any liabilities associated with indemnities.
	The Company, as permitted under Delaware law and in accordance with its amended and restated certificate of incorporation and amended and restated bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The duration of these indemnifications, commitments, and guarantees varies and, in certain cases, is indefinite. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable. No such losses have been recorded to date.
	Environmental Liabilities. The Company’s operations are subject to environmental laws and regulations adopted by various governmental authorities in the jurisdictions in which it operates. These laws require the Company to investigate and remediate the effects of the release or disposal of materials at its locations. Accordingly, the Company has adopted policies, practices and procedures in the areas of pollution control, occupational health and the production, handling, storage and use of hazardous materials to prevent material environmental or other damage, and to limit the financial liability which could result from such events. Environmental liabilities are recorded when the Company’s liability is probable and the costs can be reasonably estimated. No environmental liabilities have been recorded as of September 30, 2014.

Fair_Value_Measurements

Fair Value Measurements

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements

13. Fair Value Measurements

Accounting standards define fair value, outline a framework for measuring fair value, and detail the required disclosures about fair value measurements. Under these standards, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. Standards establish a hierarchy in determining the fair market value of an asset or liability. The fair value hierarchy has three levels of inputs, both observable and unobservable. Standards require the utilization of the highest possible level of input to determine fair value.

Level 1 – inputs include quoted market prices in an active market for identical assets or liabilities.

Level 2 – inputs are market data, other than Level 1, that are observable either directly or indirectly. Level 2 inputs include quoted market prices for similar assets or liabilities, quoted market prices in an inactive market, and other observable information that can be corroborated by market data.

Level 3 – inputs are unobservable and corroborated by little or no market data.

Cash and Cash Equivalents. For cash and cash equivalents, the fair value, based upon Level 1 inputs, approximates carrying value due to the short-term nature of these instruments.

Inventories. The Company records its inventory, primarily corn inventory, at fair value only when the Company’s cost of corn purchased exceeds the market value for corn. The Company determines the market value of corn based upon Level 1 inputs using quoted market prices. The Company incurred a write-down of inventory of $0.2 million during the three and nine months ended September 30, 2014. During the three and nine months ended September 30, 2013, the Company incurred a $0.6 million write-down of its corn inventory to market prices.

Derivative Assets and Liabilities. The fair value of exchange-traded derivative instruments is based on Level 1 inputs using quoted market prices. Exchange-traded derivative instruments are recorded in the consolidated balance sheets at fair value. The Company did not have any exchange-traded derivative instruments at September 30, 2014 or December 31, 2013.

The fair value of the Company’s forward contract derivative instruments are derived based upon a market approach using Level 2 inputs, including the price at the delivery location adjusted for basis differentials, counterparty credit quality, the effect of the Company’s own credit worthiness, the time value of money and/or the liquidity of the market. The Company did not have any forward contract derivative instruments at September 30, 2014 or December 31, 2013.

Secured Debt. The Company has estimated the fair value of its secured debt obligations based upon discounted cash flows with Level 3 inputs, such as the terms that management believes would currently be available to the Company for similar issues of debt, taking into account the current credit risk of the Company and other market factors. In May 2014 the Company entered into an amended agreement with TriplePoint in which the loans outstanding were settled in exchange for a new loan with a May 2017 maturity date for $1.0 million which amortizes over 36 months and bears interest at a rate equal to 9% per annum. The Company has determined that the estimated fair value approximates book value as of September 30, 2014.

The following table sets forth the principal balance of the Company’s secured debt obligations and the associated estimated fair value (in thousands) as of September 30, 2014.

30-Sep-14

Issuance

Principal Balance

Estimated Fair Value

TriplePoint - May 2014 Advance

897

839

The following table sets forth the principal balance of the Company’s secured debt obligations and the associated estimated fair value (in thousands) for the periods indicated.

30-Sep-14

31-Dec-13

Issuance

Principal Balance

Estimated Fair Value

Principal Balance

Estimated Fair Value

TriplePoint - September 2010 Advance

917

847

TriplePoint - October 2011 Advance

6,657

5,942

TriplePoint - January 2012 Advance

3,495

3,079

2017 Notes. The Company has estimated the fair value of the 2017 Notes, to be $25.6 million at September 30, 2014 based upon Level 2 inputs, including the market price of the Company’s common stock. The Company has valued the 2017 Notes and all of its components using the fair value option as there are no embedded instruments which qualify for equity presentation. See Note 7 for the fair value inputs used to estimate the fair value of the 2017 Notes. On the date of issuance in May 2014, the 2017 Notes were a term loan and recorded at fair value at that date.

2022 Notes Embedded Derivative. The Company has estimated the fair value of the 2022 Notes, including the embedded derivative, to be $18.9 million and $15.9 million at September 30, 2014 and December 31, 2013, respectively, based upon Level 3 inputs, including the market price of the 2022 Notes derived from actual trades of the 2022 Notes. The Company had estimated the fair value of the embedded derivative on a stand-alone basis to be $3.5 million at December 31, 2013, based upon Level 2 inputs. There estimated fair value of the embedded derivative was $0 million on a stand-alone basis at September 30, 2014. See Note 5 above for the fair value inputs used to estimate the fair value of the 2022 Notes with and without the embedded derivative and the fair value of the embedded derivative.

Derivative Warrant Liability. In December 2013, the Company issued warrants to purchase 21,303,750 shares of the Company’s common stock. Based on the terms of the warrants, the Company determined the warrants qualify as a derivative and, as such, are presented as a derivative warrant liability on the consolidated balance sheets and recorded at fair value each reporting period. The Company determined the estimated fair value of the warrants as of December 31, 2013 to be $7.2 million based upon Level 1 inputs, the quoted market prices of the warrants on such date. The Company determined the estimated fair value of the warrants as of September 30, 2014 to be $1.3 million based upon Level 2 inputs utilizing an analysis of actual historical market trades of the warrants and Black Scholes model. The Company relied on Level 2 inputs for estimating the fair value of the warrants as of September 30, 2014 due to the lack of market trades of the warrants on September 30, 2014.

In August of 2014, the Company issued warrants to purchase 15,000,000 shares of the Company’s common stock. Based on the terms of the warrants, the Company determined the warrants qualify as a derivative and, as such, are presented as a derivative warrant liability on the consolidated balance sheets and recorded at fair value each reporting period. The Company determined the estimated fair value of the warrants as of September 30, 2014 to be $1.6 million based upon Level 2 inputs utilizing an analysis of actual historical market trades of the warrants. The Company relied on Level 2 inputs for estimating the fair value of the warrants as of September 30, 2014 due to the lack of market trades of the warrants on September 30, 2014.

While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Information_on_Business_Segmen

Information on Business Segments	9 Months Ended
Information on Business Segments	Sep. 30, 2014
Segment Reporting [Abstract]	'
Information on Business Segments	'
	14. Information on Business Segments
	The Company’s chief operating decision maker is provided with and reviews the financial results of each of the Company’s consolidated legal entities, Gevo, Gevo Development, and Agri-Energy. The Company organizes its business segments based on the nature of the products and services offered through each of the Company’s consolidated legal entities. All revenue is earned, and all assets are held, in the U.S.
	The financial results of Gevo Development and Agri-Energy have been aggregated in the following table as this segment has historically been responsible for the production of ethanol and related products and will be responsible for the production of isobutanol and related products.

		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Revenues:
	Gevo	$	944		$	1,039		$	4,046		$	3,112
	Gevo Development / Agri-Energy		9,197			88			14,719			3,417
	Consolidated	$	10,141		$	1,127		$	18,765		$	6,529

	Loss from operations:
	Gevo	$	(6,133	)	$	(10,911	)	$	(19,966	)	$	(32,228	)
	Gevo Development / Agri-Energy		(2,779	)		(4,852	)		(10,900	)		(10,285	)
	Consolidated	$	(8,912	)	$	(15,763	)	$	(30,866	)	$	(42,513	)

	Interest expense:
	Gevo	$	2,558		$	1,023		$	8,471		$	4,735
	Gevo Development / Agri-Energy		40			710			1,522			2,586
	Consolidated	$	2,598		$	1,733		$	9,993		$	7,321

	Depreciation expense:
	Gevo	$	236		$	280		$	716		$	907
	Gevo Development / Agri-Energy		1,374			584			2,498			1,651
	Consolidated	$	1,610		$	864		$	3,214		$	2,558

	Acquisitions of plant, property and equipment:
	Gevo	$	27		$	180		$	76		$	442
	Gevo Development / Agri-Energy		689			1,586			4,477			4,082
	Consolidated	$	716		$	1,766		$	4,553		$	4,524

		September 30,			December 31,
		2014			2013
	Total assets:
	Gevo	$	104,503		$	100,888
	Gevo Development / Agri-Energy		52,694			65,281
	Intercompany eliminations		(49,716	)		(49,814	)
	Consolidated	$	107,481		$	116,355

Nature_of_Business_Financial_C1

Nature of Business, Financial Condition and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Nature of Business	'
	Nature of Business. Gevo, Inc. (“Gevo” or the “Company,” which, unless otherwise indicated, refers to Gevo, Inc. and its subsidiaries) is a renewable chemicals and next generation biofuels company focused on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Gevo, Inc. was incorporated in Delaware on June 9, 2005. Gevo, Inc. formed Gevo Development, LLC (“Gevo Development”) in September 2009 to finance and develop biorefineries either through joint venture, licensing arrangements, tolling arrangements or direct acquisition (see Note 9). Gevo Development became a wholly owned subsidiary of the Company in September 2010. Gevo Development purchased Agri-Energy, LLC (“Agri-Energy”) in September 2010. Through May 2012, Agri-Energy, a wholly owned subsidiary of Gevo Development, was engaged in the business of producing and selling ethanol and related products produced at its plant located in Luverne, Minnesota (the “Agri-Energy Facility”). The Company commenced the retrofit of the Agri-Energy Facility in 2011 and commenced initial startup operations for the production of isobutanol at this facility in May 2012. In September 2012, the Company made the strategic decision to pause isobutanol production at the Agri-Energy Facility to focus on optimizing specific parts of the process to further enhance isobutanol production rates. In 2013, the Company modified the Agri-Energy Facility in order to increase the isobutanol production rate. In June 2013, the Company resumed the limited production of isobutanol, operating one fermenter and one Gevo Integrated Fermentation Technology® (“GIFT®”) separation system in order to (i) verify that the modifications had significantly reduced the previously identified infections, (ii) demonstrate that its biocatalyst performs in the one million liter fermenters at the Agri-Energy Facility, and (iii) confirm GIFT® efficacy at commercial scale at the Agri-Energy Facility. In August 2013, the Company expanded production capacity at the Agri-Energy Facility by adding a second fermenter and second GIFT® system to further verify its results with a second configuration of equipment. In October 2013, the Company began commissioning the Agri-Energy Facility on corn mash to test isobutanol production run rates and to optimize biocatalyst production, fermentation separation and water management systems. In March 2014, the Company decided to leverage the flexibility of its GIFT® technology and further modify the Agri-Energy Facility which it believes will enable the simultaneous production of isobutanol and ethanol. In July 2014, the Company began more consistent co-production of isobutanol and ethanol at the Agri-Energy Facility, with one fermenter utilized for isobutanol production and three fermenters utilized for ethanol production. In line with the Company’s strategy to maximize asset utilization and site cash flows, the Company believes that this configuration of the plant should allow it to continue to optimize its isobutanol technology at a commercial scale, while taking advantage of the positive ethanol contribution margins currently available in the marketplace.
	At September 30, 2014, the Company continues to conduct research and development, business development, business and financial planning, establishing its facilities including retrofitting the Agri-Energy Facility, initial startup operations for isobutanol production at the Agri-Energy Facility and raising capital. Ultimately, the Company believes that the attainment of profitable operations is dependent upon future events, including completion of its development activities resulting in commercial production and sales of isobutanol or isobutanol-derived products and/or technology, obtaining adequate financing to complete its development activities, obtaining adequate financing to build out further isobutanol production capacity, gaining market acceptance and demand for its products and services, and attracting and retaining qualified personnel.
	The Company has primarily derived revenue from the sale of ethanol, distiller’s grains and other related products produced as part of the ethanol production process at the Agri-Energy Facility. The production of ethanol alone is not the Company’s intended business and its future strategy is expected to depend on its ability to produce and market isobutanol and products derived from isobutanol. Given that the production of ethanol alone is not the Company’s intended business, and the Company is only beginning to achieve more consistent production and revenue from the sale of isobutanol, the historical operating results of Agri-Energy may not be indicative of future operating results for Agri-Energy or Gevo.


Financial Condition	'
	Financial Condition. For the three and nine months ended September 30, 2014, the Company incurred a consolidated net loss of $0.9 million and $30.1 million, respectively, and had an accumulated deficit of $292.2 million. The Company’s cash and cash equivalents at September 30, 2014 totaled $14.0 million which is primarily being used for the following: (i) operating activities and completion of the side-by-side configuration of the Agri-Energy Facility; (ii) operating activities at its corporate headquarters in Colorado, including research and development work; (iii) capital improvements primarily associated with its Agri-Energy Facility; (iv) costs associated with optimizing isobutanol production technology; (v) costs associated with the ongoing litigation with Butamax Advanced Biofuels LLC (“Butamax”), a joint venture between British Petroleum (“BP”), E.I. du Pont de Nemours and Company (“DuPont”), and Dupont and BP Biofuels; and (vi) debt service obligations. The Company expects to incur future net losses as it continues to fund the development and commercialization of its product candidates. The Company’s transition to profitability is dependent upon, among other things, the successful development and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability or positive cash flows, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources, it may seek to restructure its debt and it will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds, or achieve or sustain profitability or positive cash flows from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. Based on the Company’s current operating plan, the Company believes that the current levels of cash will fund planned operations into 2015 without additional sources of cash.
	Despite the Company’s continued success in meeting isobutanol fermentation targets, producing isobutanol and ethanol simultaneously, and its progress toward achieving breakeven earnings before interest, taxes, depreciation and amortization (EBITDA) at the Agri-Energy Facility, the Company continues to face significant expenses related to its ongoing litigation with Butamax. While the United States District Court has temporarily stayed the litigation with Butamax involving certain patents, trials related to other patents were recently scheduled for August 2015 and April 2016 and the Company expects to incur significant costs preparing for and participating in these upcoming trials. The Company continues to believe that the Butamax complaints are without merit. However, if it is unable to raise the significant funds that will be required for it to continue to defend its freedom to operate, the Company could be forced to change its business strategy which may include one or more of the following: (i) terminating the research and development, manufacture, sale and use of products that include the subject intellectual property; (ii) conducting research and development and manufacturing any products that include the subject intellectual property outside of the United States; (iii) shifting its focus to the production of ethanol and/or the development of hydrocarbon products, including those that can be produced from ethanol; or (iv) pursuing strategic alternatives, including the monetization of some or all of the Company’s assets, in order to maximize stockholder value.
Basis of Presentation	'
	Basis of Presentation. The unaudited consolidated financial statements of the Company (which include the accounts of its wholly-owned subsidiaries Gevo Development and Agri-Energy) have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. These statements reflect all normal and recurring adjustments which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows of the Company at September 30, 2014 and for all periods presented. The consolidated statements of operations for the three and nine months ended September 30, 2014 and consolidated statements of cash flows for the nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto included under the heading “Financial Statements and Supplementary Data” in Part II, Item 8 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (the “Annual Report”).

	Significant accounting policies. The Company has elected the fair value option for certain long-term debt instruments that qualify for such treatment. See Note 7 for a detailed description of the accounting for the 2017 convertible notes that are accounted for in this manner. The Company also placed into service the Retrofit asset (as defined below) in July of 2014 and began depreciating the asset over a 20 year useful life.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014‑09”). The objective of ASU 2014-09 is to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014‑09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014‑09.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). The amendments in ASU 2014-10 remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification®. ASU 2014-10 is effective for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted and the Company adopted ASU 2014-10 in the third quarter of 2014 which consisted principally of removing Inception to date information on the Company’s statements of operations, equity and cash flows as well as other inception to date disclosures in the notes to the consolidated financial statements.

Earnings_per_Share_Tables

Earnings per Share (Tables)	9 Months Ended
Earnings per Share (Tables)	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Securities that Potentially Dilute Calculation of Diluted Earnings Per Share	'
	The following table sets forth securities outstanding that could potentially dilute the calculation of diluted earnings per share.

		Nine Months Ended September 30,
		2014		2013
	Warrants to purchase common stock		37,563,548		1,259,998
	Convertible 2017 notes		22,537,983		-
	Convertible 2022 notes		4,725,516		4,725,392
	Outstanding options to purchase common stock		3,741,150		3,172,213
	Unvested restricted common stock		1,010,220		1,033,731
	Total		69,578,417		10,191,334

Inventories_Tables

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Components of Inventory Balances	'
	The following table sets forth the components of the Company’s inventory balances (in thousands).

		September 30,		December 31,
		2014		2013
	Raw materials
	Corn	$	1,376	$	1,456
	Enzymes and other inputs		376		514
	Finished goods		623		192
	Work in process		228		224
	Spare parts		1,424		1,195

	Total inventories	$	4,027	$	3,581

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	9 Months Ended
Property, Plant and Equipment (Tables)	Sep. 30, 2014
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment by Classification	'
	The following table sets forth the Company’s property, plant and equipment by classification (in thousands).

		Useful	September 30,			December 31,
		Life	2014			2013
	Construction in progress	-	$	356		$	66,033
	Plant machinery and equipment	10 years		13,093			11,009
	Site improvements	10 years		7,009			7,007
	Retrofit asset	20 years		65,659			-
	Lab equipment, furniture and fixtures and vehicles	5 years		6,369			6,303
	Demonstration plant	2 years		3,597			3,597
	Buildings	10 years		2,543			2,543
	Computer, office equipment and software	3 years		1,465			1,437
	Leasehold improvements, pilot plant, land and support equipment	2 - 5 years		2,143			2,105
	Total property, plant and equipment			102,234			100,034
	Less accumulated depreciation and amortization			(19,724	)		(16,559	)

	Property, plant and equipment, net		$	82,510		$	83,475

Derivative_Instruments_Tables

Derivative Instruments (Tables)	9 Months Ended
Derivative Instruments (Tables)	Sep. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Summary of Realized and Unrealized Gains/(Losses) of Derivative Instruments	'
	The following table summarizes the realized and unrealized gain / (loss) of the Company’s derivative instruments (in thousands).

		Three Months Ended September 30,						Nine Months Ended September 30,
	Realized Gain / (Losses)	2014			2013			2014		2013
	Exchange-traded futures contracts	$	-		$	168		$	-	$	490

	Unrealized Gain / (Losses)
	Exchange-traded futures contracts		-			42			-		(176	)
	Forward purchase contracts		-			(11	)		-		1

Input to Lattice Model that was Used to Value Embedded Derivative	'
	The following table sets forth the inputs to the lattice model that were used to value the embedded derivative.

		September 30,			December 31,
		2014			2013
	Stock price	$	0.34		$	1.43
	Conversion Rate		175.6697			175.6697
	Conversion Price	$	5.69		$	5.69
	Maturity date	1-Jul-22			1-Jul-22
	Risk-free interest rate		2.3	%		2.8	%
	Estimated stock volatility		85	%		65	%
	Estimated credit spread		20	%		33	%

2022 Notes With and Without Embedded Derivative and Fair Value of Embedded Derivative	'
	The following table sets forth the value of the 2022 Notes with and without the embedded derivative, and the fair value of the embedded derivative (in thousands).

		September 30,			December 31,
		2014			2013
	Fair value of Convertible Notes:
	With the embedded derivative	$	18,938		$	15,925
	Without the embedded derivative		18,938			12,455
	Estimated fair value of the embedded derivative	$	-		$	3,470

Accounts_Payable_and_Accrued_L1

Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
Accounts Payable and Accrued Liabilities (Tables)	Sep. 30, 2014
Payables And Accruals [Abstract]	'
Components of Accounts Payable and Accrued Liabilities in Consolidated Balance Sheets	'
	The following table sets forth the components of the Company’s accounts payable and accrued liabilities in the consolidated balance sheets (in thousands).

		September 30,		December 31,
		2014		2013
	Accounts payable — trade	$	2,760	$	6,460
	Accrued legal-related fees		2,237		2,999
	Deferred revenue		-		1,000
	Accrued employee compensation		947		818
	Other accrued liabilities		1,489		1,753
	Total accounts payable and accrued liabilities	$	7,433	$	13,030

Secured_Debt_and_Convertible_N1

Secured Debt and Convertible Notes (Tables)	9 Months Ended
Secured Debt and Convertible Notes (Tables)	Sep. 30, 2014
Debt Instrument [Line Items]	'
Inputs to Lattice Model used to Value Term Loan and 2017 Notes for which Fair Value Option was Elected	'
	The following table sets forth the inputs to the lattice model that were used to value the Term Loan and 2017 Notes for which the fair value option was elected.

		September 30,
		2014
	Stock price	$	0.34
	Conversion Rate		863.3
	Conversion Price	$	1.16
	Maturity date	15-Mar-17
	Risk-free interest rate		0.8	%
	Estimated stock volatility		85	%
	Estimated credit spread		15	%


Information Pertaining to Convertible Notes	'
	The following table sets forth information pertaining to the Term Loan and 2017 Notes which is included in the Company’s consolidated balance sheets (in thousands).


		Principal Amount of Term Loans			Principal Amount of 2017 Notes			Change in Estimated Fair Value			Total
	Balance - December 31, 2013	$	-		$	-		$	-		$	-
	Issuance of Term Loan		25,907			-			-			25,907
	Exchange of Term Loan for 2017 Notes		(25,907	)		25,907			-			-
	Non-cash paid-in-kind interest expense		-			201			-			201
	Gain from change in fair value of debt		-			-			(544	)		(544	)
	Balance - September 30, 2014	$	-		$	26,108		$	(544	)	$	25,564
	Changes in certain inputs into the lattice model can have a significant impact on changes in the estimated fair value of the Term Loan and 2017 Notes. For example, the estimated fair value will generally decrease with; (1) a decline in the stock price; (2) increases in the estimated stock volatility; and (3) an increase in the estimated credit spread. The change in the estimated fair value of the 2017 Notes during the three and nine months ended September 30, 2014, represents an unrealized gain which has been recorded as gain from change in fair value of 2017 Notes in the consolidated statements of operations.

Secured Debt Included in Consolidated Balance Sheets	'
	The following table sets forth information pertaining to the Company’s secured debt issued to TriplePoint Capital LLC (“TriplePoint”) which is included in the Company’s consolidated balance sheets (in thousands).

		September 30,			December 31,
		2014			2013
	Secured debt
	TriplePoint - September 2010 Advance	$	-		$	917
	TriplePoint - October 2011 Advance		-			6,657
	TriplePoint - January 2012 Advance		-			3,495
	TriplePoint - May 2014 Advance		897			-
	Total secured debt		897			11,069
	Less:
	Unamortized debt discounts		(58	)		(942	)
			839			10,127
	Less current portion of debt		(253	)		(788	)
	Long-term portion of debt	$	586		$	9,339


2022 Notes	'
Debt Instrument [Line Items]	'
Information Pertaining to Convertible Notes	'
	The following table sets forth information pertaining to the 2022 Notes which is included in the Company’s consolidated balance sheets (in thousands).

		Embedded Derivatives			Principal Amount of 2022 Notes			Debt Discount			Total
	Balance - December 31, 2012	$	11,000		$	45,000		$	(30,446	)	$	25,554
	Amortization of debt discount		-			-			2,780			2,780
	Write-off of debt discount associated with conversion of debt		-			-			11,277			11,277
	Gain from change in fair value of embedded derivatives		(2,280	)		-			-			(2,280	)
	Conversion		(4,416	)		(18,100	)		-			(22,516	)
	Balance - September 30, 2013	$	4,304		$	26,900		$	(16,389	)	$	14,815

		Embedded Derivatives			Principal Amount of 2022 Notes			Debt Discount			Total
	Balance - December 31, 2013	$	3,470		$	26,900		$	(15,869	)	$	14,501
	Amortization of debt discount		-			-			1,889			1,889
	Gain from change in fair value of embedded derivatives		(3,470	)		-			-			(3,470	)
	Balance - September 30, 2014	$	-		$	26,900		$	(13,980	)	$	12,920

Gevo_Development_Tables

Gevo Development (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Net Loss Incurred by Gevo Development	'
	The following table sets forth (in thousands) the net loss incurred by Gevo Development (including Agri-Energy after September 22, 2010, the closing date of the acquisition) which has been fully allocated to Gevo, Inc.’s capital contribution account based upon its capital contributions (for the period prior to September 2010) and 100% ownership (for the period after September 22, 2010).

		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Gevo Development Net Loss	$	(2,808	)	$	(5,559	)	$	(12,411	)	$	(12,862	)

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
Stock-Based Compensation (Tables)	Sep. 30, 2014
Share Based Compensation [Abstract]	'
Stock-Based Compensation Expense	'
	The following table sets forth the Company’s stock-based compensation expense (in thousands) for the periods indicated.

		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Stock options and employee stock purchase plan awards
	Research and development	$	96	$	172	$	355	$	507
	Selling, general and administrative		225		411		764		1,499

	Restricted stock awards
	Research and development		90		-		361		-
	Selling, general and administrative		448		374		882		1,038

	Warrants issued
	Selling, general and administrative		-		-		-		39
	Non-cash stock-based compensation		859		957		2,362		3,083

	Modified stock option awards
	Selling, general and administrative		-		-		-		-

	Purchase of Class B interests of Gevo Development from CDP for cash
	Selling, general and administrative		-		-		-		-
	Cash stock-based compensation		-		-		-		-

	Total stock-based compensation	$	859	$	957	$	2,362	$	3,083

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Estimate of Fair Value of Secured Debt Obligations	'
	The following table sets forth the principal balance of the Company’s secured debt obligations and the associated estimated fair value (in thousands) as of September 30, 2014.

		30-Sep-14
	Issuance	Principal Balance		Estimated Fair Value
	TriplePoint - May 2014 Advance	$	897	$	839

	The following table sets forth the principal balance of the Company’s secured debt obligations and the associated estimated fair value (in thousands) for the periods indicated.

		30-Sep-14				31-Dec-13
	Issuance	Principal Balance		Estimated Fair Value		Principal Balance		Estimated Fair Value

	TriplePoint - September 2010 Advance	$	-	$	-	$	917	$	847
	TriplePoint - October 2011 Advance		-		-		6,657		5,942
	TriplePoint - January 2012 Advance		-		-		3,495		3,079

Information_on_Business_Segmen1

Information on Business Segments (Tables)	9 Months Ended
Information on Business Segments (Tables)	Sep. 30, 2014
Segment Reporting [Abstract]	'
Summary of Segment Information	'
	The financial results of Gevo Development and Agri-Energy have been aggregated in the following table as this segment has historically been responsible for the production of ethanol and related products and will be responsible for the production of isobutanol and related products.

		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Revenues:
	Gevo	$	944		$	1,039		$	4,046		$	3,112
	Gevo Development / Agri-Energy		9,197			88			14,719			3,417
	Consolidated	$	10,141		$	1,127		$	18,765		$	6,529

	Loss from operations:
	Gevo	$	(6,133	)	$	(10,911	)	$	(19,966	)	$	(32,228	)
	Gevo Development / Agri-Energy		(2,779	)		(4,852	)		(10,900	)		(10,285	)
	Consolidated	$	(8,912	)	$	(15,763	)	$	(30,866	)	$	(42,513	)

	Interest expense:
	Gevo	$	2,558		$	1,023		$	8,471		$	4,735
	Gevo Development / Agri-Energy		40			710			1,522			2,586
	Consolidated	$	2,598		$	1,733		$	9,993		$	7,321

	Depreciation expense:
	Gevo	$	236		$	280		$	716		$	907
	Gevo Development / Agri-Energy		1,374			584			2,498			1,651
	Consolidated	$	1,610		$	864		$	3,214		$	2,558

	Acquisitions of plant, property and equipment:
	Gevo	$	27		$	180		$	76		$	442
	Gevo Development / Agri-Energy		689			1,586			4,477			4,082
	Consolidated	$	716		$	1,766		$	4,553		$	4,524

		September 30,			December 31,
		2014			2013
	Total assets:
	Gevo	$	104,503		$	100,888
	Gevo Development / Agri-Energy		52,694			65,281
	Intercompany eliminations		(49,716	)		(49,814	)
	Consolidated	$	107,481		$	116,355

Nature_of_Business_Financial_C2

Nature of Business, Financial Condition and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'	'	'	'	'
Net loss	($938)	($15,885)	($30,066)	($49,477)	'	'
Deficit accumulated	-292,219	'	-292,219	'	-262,153	'
Cash and cash equivalents	$14,010	$25,661	$14,010	$25,661	$24,625	$66,744

Securities_that_Potentially_Di

Securities that Potentially Dilute Calculation of Diluted Earnings Per Share (Detail)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Warrants to purchase common stock	69,578,417	10,191,334
Warrants to purchase common stock	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Warrants to purchase common stock	37,563,548	1,259,998
Convertible 2017 Notes	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Warrants to purchase common stock	22,537,983	'
Convertible 2022 Notes	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Warrants to purchase common stock	4,725,516	4,725,392
Outstanding options to purchase common stock	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Warrants to purchase common stock	3,741,150	3,172,213
Unvested restricted common stock	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Warrants to purchase common stock	1,010,220	1,033,731

Components_of_Inventory_Balanc

Components of Inventory Balances (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Finished goods	$623	$192
Work in process	228	224
Spare parts	1,424	1,195
Total inventories	4,027	3,581
Corn	'	'
Inventory [Line Items]	'	'
Raw materials	1,376	1,456
Enzymes And Other Inputs	'	'
Inventory [Line Items]	'	'
Raw materials	$376	$514

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Inventory Disclosure [Abstract]	'	'	'	'
Depreciation	$1.40	$0.50	$2.50	$1.60

Property_Plant_and_Equipment_b

Property, Plant and Equipment by Classification (Detail) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

In Thousands, unless otherwise specified

Construction in progress

Plant machinery and equipment

Site improvements

Retrofit Asset

Lab equipment, furniture and fixtures and vehicles

Demonstration plant

Buildings

Computer, office equipment and software

Leasehold improvements, pilot plant, land and support equipment

Minimum

Maximum

Property Plant And Equipment [Line Items]

Property, plant and equipment, useful life

'10 years

'20 years

'5 years

'2 years

'10 years

'3 years

'2 years

'5 years

Total property, plant and equipment

$102,234

$100,034

$356

$66,033

$13,093

$11,009

$7,009

$7,007

$65,659

$6,369

$6,303

$3,597

$2,543

$1,465

$1,437

$2,143

$2,105

Less accumulated depreciation and amortization

-19,724

-16,559

Property, plant and equipment, net

$82,510

$83,475

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Property Plant And Equipment [Line Items]	'	'	'	'
Capitalized interest expense	$0	$0.10	$0	$0.20
Retrofit Asset	'	'	'	'
Property Plant And Equipment [Line Items]	'	'	'	'
Property, plant and equipment, useful life	'20 years	'	'20 years	'

Summary_of_Realized_and_Unreal

Summary of Realized and Unrealized Gains/(Losses) of Derivative Instruments (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Derivative Instruments Gain Loss [Line Items]	'	'	'	'
Derivative instrument, gain (loss)	'	'	'	($175)
Exchange-traded futures contracts	'	'	'	'
Derivative Instruments Gain Loss [Line Items]	'	'	'	'
Derivative instrument, gain (loss)	0	42	0	-176
Forward purchase contracts	'	'	'	'
Derivative Instruments Gain Loss [Line Items]	'	'	'	'
Derivative instrument, gain (loss)	0	-11	0	1
Realized Gain / (Losses) \| Exchange-traded futures contracts	'	'	'	'
Derivative Instruments Gain Loss [Line Items]	'	'	'	'
Derivative instrument, gain (loss)	$0	$168	$0	$490

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended		1 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Aug. 31, 2014	Sep. 30, 2014	Jul. 31, 2012	Sep. 30, 2014
	Aug. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	2013 Warrants	2013 Warrants	2014 Warrants	2014 Warrants	2022 Notes	2022 Notes
Derivative [Line Items]	'	'	'	'	'	'	'	'	'
Percentage of convertible senior notes embedded derivatives	'	'	'	'	'	'	'	7.50%	'
Convertible senior notes due date	'	'	'	'	'	'	'	'2022	'
2022 notes, conversion date	'	'	'	'	'	'	'	1-Jul-17	1-Jul-17
Common stock shares issued and sold	15,000,000	21,303,750	'	21,303,750	'	'	'	'	'
Warrant , Exercise Price	'	'	$1.18	$1.43	'	$0.85	'	'	'
Warrants expiration date	'	'	'	'	16-Dec-18	'	5-Aug-19	'	'
Common stock shares issued	'	68,492,894	99,592,898	'	'	30,000,000	'	'	'
Additional purchase of common stock shares	'	'	'	'	'	15,000,000	'	'	'
Derivative warrant liability fair value	'	$7,243	$2,877	'	'	'	'	'	'

Input_to_Lattice_Model_that_wa

Input to Lattice Model that was Used to Value Embedded Derivative (Detail) (2022 Notes, Embedded Derivative Financial Instruments, USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
2022 Notes \| Embedded Derivative Financial Instruments	'	'
Derivative [Line Items]	'	'
Stock price	$0.34	$1.43
Conversion Rate	175.6697	175.6697
Conversion Price	$5.69	$5.69
Maturity date	1-Jul-22	1-Jul-22
Risk-free interest rate	2.30%	2.80%
Estimated stock volatility	85.00%	65.00%
Estimated credit spread	20.00%	33.00%

2022_Notes_with_and_without_Em

2022 Notes with and without Embedded Derivative and Fair Value of Embedded Derivative (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Fair value of Convertible Notes:	'	'
With the embedded derivative	$18,938	$15,925
Without the embedded derivative	18,938	12,455
Estimated fair value of the embedded derivative	'	$3,470

Components_Accounts_Payable_an

Components Accounts Payable and Accrued Liabilities in Consolidated Balance Sheets (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Payables And Accruals [Abstract]	'	'
Accounts payable b trade	$2,760	$6,460
Accrued legal-related fees	2,237	2,999
Deferred revenue	'	1,000
Accrued employee compensation	947	818
Other accrued liabilities	1,489	1,753
Total accounts payable and accrued liabilities	$7,433	$13,030

Secured_Debt_and_Convertible_N2

Secured Debt and Convertible Notes - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

31-May-14

Jul. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Jan. 31, 2012

Oct. 31, 2011

Jun. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Jun. 30, 2014

Aug. 31, 2010

Oct. 31, 2011

Sep. 30, 2014

31-May-14

Sep. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Jul. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

31-May-14

Dec. 31, 2013

31-May-14

Aug. 31, 2010

Sep. 30, 2014

Warrant

First Installment

Term Loans

Gevo Loan

Amended Agri Energy Loan Agreement

Convertible 2017 Notes

2022 Notes

Restructure Period

Loan Agreement

May 2014 Amendments

Interest Payable In Cash

Interest Payable In Kind

First Installment

Final Installment

Term Loans

Coupon Make-Whole Payments

Make-Whole Fundamental Change

Fundamental Change

Provisional Redemption

Amended Agri Energy Loan Agreement

Term Loans

Original Agri-Energy Loan Agreement

Maximum

First Installment

Debt Instrument [Line Items]

Debt instrument maturity date

15-Mar-17

1-Jul-22

15-Mar-17

31-May-17

Line of credit, maximum borrowing capacity

$31,100,000

Line of Credit Facility, Current Borrowing Capacity

22,800,000

Secured debt, discount

1,600,000

Debt issuance cost

581,000

3,766,000

1,400,000

1,500,000

Convertible senior secured note, percentage of stock price

10.00%

90.00%

Outstanding principal amount of term loan

25,900,000

5,000,000

12,500,000

Accrued paid in kind interest

200,000

201,000

200,000

Conversion Price

$1.16

$5.69

Debt Conversion, Description

'The 2017 Notes have a conversion price (the bConversion Priceb) equal to $1.1584 per share or .8663 shares per $1 principal amount of 2017 Notes.

Conversion Rate

0.8663

863.3

175.6697

202.0202

Restricted deposits

2,611,000

Debt instrument, interest rate

11.00%

15.00%

5.00%

10.00%

7.50%

Common stock, shares authorized

250,000,000

17,500,000

Debt instrument, face amount

26,100,000

Estimated fair value of principal amount

25,564,000

26,108,000

25,564,000

18,900,000

15,900,000

Interest expense

2,017,000

1,733,000

6,227,000

7,321,000

600,000

900,000

500,000

1,500,000

1,800,000

Proceeds from 2022 notes

5,400,000

End-of-term payment as percentage of amount borrowed

8.00%

Proceeds from issuance of common stock and common stock units

18,000,000

5,100,000

Loan and security agreement outstanding principal amount

5,100,000

Debt instrument, additional term loan

15,000,000

Debt Instrument, repurchase amount

15,000,000

5,000,000

10,000,000

Number of warrants outstanding

Number of shares of common stock exercisable for warrants

388,411

Exercise price of common stock

$1.18

Percentage of convertible senior notes embedded derivatives

7.50%

13.00%

Percentage of payment on principal amount and interest due

50.00%

Aggregate principal amount on sale of convertible notes

45,000,000

Proceeds from issuance of 2017 Notes, net

25,907,000

40,900,000

Non-cash interest expense

6,374,000

3,747,000

700,000

500,000

2,000,000

2,800,000

Long term debt interest rate

40.00%

Amortization period of debt discount

'5 years

Amortization period of debt issuance cost

'5 years

2022 notes, conversion date

1-Jul-17

Debt instrument, convertible, conversion price

1,000

Discount rate used in computation of interest payment

2.00%

Number of trading days for valuation

'10 days

Conversion of convertible debt to common stock

18,100,000

4,900,000

Secured debt

26,900,000

900,000

Debt Conversion, Converted Instrument, Shares Issued

3,179,608

2,957,775

Percentage repurchase price

100.00%

Number of trading days required for redemption

'20 or more trading days

Excess to percentage of conversion price

150.00%

Number of consecutive trading days required for redemption

'30 days

Debt instrument, periodic payment, principal

$9,600,000

Long term borrowing interest rate

9.00%

Schedule_of_Estimated_Fair_Val

Schedule of Estimated Fair Value Assumption of Term Loan and 2017 Notes (Detail) (Convertible 2017 Notes, USD $)	9 Months Ended
	Sep. 30, 2014
Debt Instrument [Line Items]	'
Conversion Rate	0.8663
Term Loans	'
Debt Instrument [Line Items]	'
Stock price	0.34
Conversion Rate	863.3
Conversion Price	1.16
Maturity date	15-Mar-17
Risk-free interest rate	0.80%
Estimated stock volatility	85.00%
Estimated credit spread	15.00%

Information_Pertaining_to_Term

Information Pertaining to Term Loan and 2017 Notes (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Debt Instrument [Line Items]	'	'
Balance - September 30, 2014	$25,564	$25,564
Principal Amount of Term Loans	'	'
Debt Instrument [Line Items]	'	'
Balance - December 31, 2013	'	0
Issuance of Term Loan	'	25,907
Exchange of Term Loan for 2017 Notes	'	-25,907
Accrued paid in kind interest	'	0
Gain from change in fair value of debt	'	0
Balance - September 30, 2014	0	0
Convertible 2017 Notes	'	'
Debt Instrument [Line Items]	'	'
Balance - December 31, 2013	'	0
Issuance of Term Loan	'	0
Exchange of Term Loan for 2017 Notes	'	25,907
Accrued paid in kind interest	'	201
Gain from change in fair value of debt	'	0
Balance - September 30, 2014	26,108	26,108
Convertible 2017 Notes \| Principal Amount of Term Loans	'	'
Debt Instrument [Line Items]	'	'
Accrued paid in kind interest	200	200
Balance - September 30, 2014	25,564	25,564
Term Loan And2017 Notes	'	'
Debt Instrument [Line Items]	'	'
Balance - December 31, 2013	'	0
Issuance of Term Loan	'	25,907
Exchange of Term Loan for 2017 Notes	'	0
Accrued paid in kind interest	'	201
Gain from change in fair value of debt	'	-544
Balance - September 30, 2014	25,564	25,564
Change in Estimated Fair Value	'	'
Debt Instrument [Line Items]	'	'
Balance - December 31, 2013	'	0
Issuance of Term Loan	'	0
Exchange of Term Loan for 2017 Notes	'	0
Accrued paid in kind interest	'	0
Gain from change in fair value of debt	'	-544
Balance - September 30, 2014	($544)	($544)

Secured_Debt_Included_in_Conso

Secured Debt Included in Consolidated Balance Sheets (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Less current portion of debt	($253)	($788)
Long-term portion of debt	561	9,339
TriplePoint Capital LLC	'	'
Debt Instrument [Line Items]	'	'
Secured debt	897	11,069
Less: Unamortized debt discounts	-58	-942
Secured debt, net	839	10,127
Less current portion of debt	-253	-788
Long-term portion of debt	586	9,339
TriplePoint Capital LLC \| TriplePoint - September 2010 Advance	'	'
Debt Instrument [Line Items]	'	'
Secured debt	'	917
TriplePoint Capital LLC \| TriplePoint - October 2011 Advance	'	'
Debt Instrument [Line Items]	'	'
Secured debt	'	6,657
TriplePoint Capital LLC \| TriplePoint - January 2012 Advance	'	'
Debt Instrument [Line Items]	'	'
Secured debt	'	3,495
TriplePoint Capital LLC \| TriplePoint - May 2014 Advance	'	'
Debt Instrument [Line Items]	'	'
Secured debt	$897	'

Information_Pertaining_to_2022

Information Pertaining to 2022 Notes (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Debt Instrument [Line Items]	'	'	'	'
Beginning balance	'	'	$14,501	$25,554
Amortization of debt discount	'	'	1,889	2,780
Write-off of debt discount associated with conversion of debt	'	'	'	11,277
Gain from change in fair value of embedded derivative of 2022 note	-726	-1,587	-3,470	-2,280
Conversion	'	'	'	-22,516
Ending balance	12,920	14,815	12,920	14,815
Embedded Derivative Financial Instruments	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Beginning balance	'	'	3,470	11,000
Amortization of debt discount	'	'	0	0
Write-off of debt discount associated with conversion of debt	'	'	'	0
Gain from change in fair value of embedded derivative of 2022 note	'	'	-3,470	-2,280
Conversion	'	'	'	-4,416
Ending balance	0	4,304	0	4,304
Principal Amount of Convertible Notes	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Beginning balance	'	'	26,900	45,000
Amortization of debt discount	'	'	0	0
Write-off of debt discount associated with conversion of debt	'	'	'	0
Gain from change in fair value of embedded derivative of 2022 note	'	'	0	0
Conversion	'	'	'	-18,100
Ending balance	26,900	26,900	26,900	26,900
Debt Discount	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Beginning balance	'	'	-15,869	-30,446
Amortization of debt discount	'	'	1,889	2,780
Write-off of debt discount associated with conversion of debt	'	'	'	11,277
Gain from change in fair value of embedded derivative of 2022 note	'	'	0	0
Conversion	'	'	'	0
Ending balance	($13,980)	($16,389)	($13,980)	($16,389)

Significant_Agreements_Additio

Significant Agreements - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

31-May-13

Mar. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2011

Jul. 31, 2011

Sep. 30, 2014

Aug. 31, 2011

Sep. 30, 2014

Aug. 31, 2011

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Aug. 31, 2011

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2013

Mar. 31, 2010

Sep. 30, 2014

Dec. 31, 2009

Sep. 30, 2014

31-May-14

Dec. 31, 2013

Boe

Maximum

Sasol

Lanxess

Mansfield

C And N

Ethanol Marketing Agreement with Subsidiary of Mansfield Oil Company

Biojet Fuel

Development and Commercialization Agreements with ICM Inc

Joint Research Development License and Commercialization Agreement with Coca-Cola Company

Cargill License Agreement

Toray Industries, Inc.

Boe

Installment

Parties To Contract [Line Items]

Agreement term

'3 years

'5 years

'3 years

Amount recorded for resale agreement

Amount recorded for supply agreement

Terms of agreement

'The ethanol purchase and marketing agreement with C&N was entered into on April 1, 2009 and automatically renews for subsequent one-year terms unless either party terminates the agreement 60 days before the end of a term.

'In December 2011, the development agreement was amended to extend the term indefinitely. The development agreement, as amended, may be cancelled by either party with 30 daysb prior written notice.

'The Company may terminate the license agreement at any time upon 90 daysb prior written notice. Unless terminated earlier, the license agreement remains in effect until the later of December 31, 2025 and the date that no licensed patent rights remain.

Production, barrels of oil Equivalents

20,000

3,650

45,000

11,000

Hydrocarbon revenue

778,000

704,000

3,426,000

2,016,000

800,000

400,000

1,600,000

1,100,000

Increase Decrease In Production Barrels Of Oil Equivalents

12,500

Commercialization Agreement Period

'2018-10

Grant and other revenue

166,000

406,000

620,000

1,168,000

300,000

900,000

Milestone payment

Royalty expense

4,300,000

Research and development expense

3,723,000

5,476,000

11,414,000

16,280,000

2,000,000

900,000

Present value of license fee

1,600,000

Royalty fee payable

1,000,000

Royalty fee payable, due date

'2015-12

License fees

500,000

Common stock shares issued

250,000

Amount received for pilot plant

1,000,000

Amount refund from pilot plant

1,000,000

Refund amount as component of other long term liabilities

$1,000,000

Gevo_Development_Additional_In

Gevo Development - Additional Information (Detail) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2010

Jan. 31, 2012

CDP Gevo, LLC

Common Class B

Gevo Development

Warrant Agreement

Warrants to purchase common stock

CDP Gevo, LLC

Securities

Common Class B

Co Managing Directors

Class Of Stock [Line Items]

Equity ownership of wholly owned subsidiary

100.00%

Outstanding interest rate

10.00%

Number of membership interests outstanding

Consideration for exchange of class B interest

$1,100,000

Non-cash stock-based compensation

2,362,000

3,083,000

2,600,000

800,000

100,000

Capital contribution to subsidiaries

1,600,000

7,000,000

24,700,000

14,100,000

Number of shares of common stock exercisable for warrants

388,411

858,000

Warrant , Exercise Price

$1.18

$2.70

Warrants expiration date

30-Sep-16

Percentage of warrant shares vested

50.00%

Remaining warrant shares vested period

'2 years

Derivative warrant liability fair value

$2,877,000

$7,243,000

$14,000,000

Net_Loss_Incurred_by_Gevo_Deve

Net Loss Incurred by Gevo Development (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Related Party Transaction [Line Items]	'	'	'	'
Net loss from operation	($938)	($15,885)	($30,066)	($49,477)
Gevo Development	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Net loss from operation	($2,808)	($5,559)	($12,411)	($12,862)

Redfield_Energy_LLC_Additional

Redfield Energy, LLC - Additional Information (Detail) (Redfield, USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014
	Person
	Boe
Redfield	'
Related Party Transaction [Line Items]	'
Redfield ethanol production facility	50,000,000
Limited partners capital account units issued	100
Members in board of managers	11
Cost for retrofit of Redfield Facilities	$0.40

StockBased_Compensation_Expens

Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation	'	'	$2,362	$3,083
Stock-based compensation	859	957	2,362	3,083
Non Cash	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation	859	957	2,362	3,083
Non Cash \| Stock options and employee stock purchase plan awards \| Research and Development Expense	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation	96	172	355	507
Non Cash \| Stock options and employee stock purchase plan awards \| Selling, General and Administrative Expense	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation	225	411	764	1,499
Non Cash \| Unvested restricted common stock \| Research and Development Expense	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation	90	0	361	0
Non Cash \| Unvested restricted common stock \| Selling, General and Administrative Expense	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation	448	374	882	1,038
Non Cash \| Warrants Issued \| Selling, General and Administrative Expense	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation	0	0	0	39
Cash Based	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation	0	0	0	0
Cash Based \| Modified Stock Option Awards \| Selling, General and Administrative Expense	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation	0	0	0	0
Cash Based \| Purchase Of Interest \| Selling, General and Administrative Expense	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation	$0	$0	$0	$0

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Aug. 31, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Jul. 31, 2012

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Principal Amount of Term Loans

Convertible 2017 Notes

2022 Notes

Two Thousand Fourteen Amendment

Fair Value, Inputs, Level 1

Fair Value, Inputs, Level 2

Corn

Principal Amount of Term Loans

Secured Debt

Warrants Issued in 2013

Warrants Issued in 2014

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Write down of inventory

$200,000

$600,000

Secured debt

26,900,000

1,000,000

Amortization period of debt issuance cost

'5 years

'36 months

Debt instrument maturity date

15-Mar-17

1-Jul-22

31-May-17

Debt instrument, stated interest rate

7.50%

9.00%

Estimated fair value of principal amount

25,564,000

26,108,000

25,564,000

18,900,000

15,900,000

Estimated fair value of the embedded derivatives

3,500,000

Common stock shares issued and sold

15,000,000

21,303,750

Derivative warrant liability fair value

$2,877,000

$7,243,000

$7,200,000

$1,300,000

$1,600,000

Estimate_of_Fair_Value_of_Secu

Estimate of Fair Value of Secured Debt Obligations (Detail) (USD $)	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified	TriplePoint - May 2014 Advance	TriplePoint - May 2014 Advance	TriplePoint - September 2010 Advance	TriplePoint - September 2010 Advance	TriplePoint - October 2011 Advance	TriplePoint - October 2011 Advance	TriplePoint - January 2012 Advance	TriplePoint - January 2012 Advance
	Principal Balance	Change in Estimated Fair Value	Principal Balance	Change in Estimated Fair Value	Principal Balance	Change in Estimated Fair Value	Principal Balance	Change in Estimated Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]	'	'	'	'	'	'	'	'
Debt instrument fair value	$897	$839	$917	$847	$6,657	$5,942	$3,495	$3,079

Information_on_Business_Segmen2

Information on Business Segments (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	$10,141	$1,127	$18,765	$6,529	'
Loss from operations	-8,912	-15,763	-30,866	-42,513	'
Interest expense	2,598	1,733	9,993	7,321	'
Depreciation expense	1,610	864	3,214	2,558	'
Acquisitions of plant, property and equipment	716	1,766	4,553	4,524	'
Total assets	107,481	'	107,481	'	116,355
Operating Segments \| Gevo	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	944	1,039	4,046	3,112	'
Loss from operations	-6,133	-10,911	-19,966	-32,228	'
Interest expense	2,558	1,023	8,471	4,735	'
Depreciation expense	236	280	716	907	'
Acquisitions of plant, property and equipment	27	180	76	442	'
Total assets	104,503	'	104,503	'	100,888
Operating Segments \| Gevo Development / Agri-Energy	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	9,197	88	14,719	3,417	'
Loss from operations	-2,779	-4,852	-10,900	-10,285	'
Interest expense	40	710	1,522	2,586	'
Depreciation expense	1,374	584	2,498	1,651	'
Acquisitions of plant, property and equipment	689	1,586	4,477	4,082	'
Total assets	52,694	'	52,694	'	65,281
Intercompany Eliminations	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Total assets	($49,716)	'	($49,716)	'	($49,814)